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ABSTRACT

The cancer epidemic continues to afflict millions of humans world-wide each year and
despite a renewed hope with the development of new and improved forms of therapy, a cure for
cancer remains an elusive goal. This is partly related to the rise of resilient forms of tumors that
have evolved with resistance towards conventional chemotherapy and radiation treatments.
Moreover, these non-specific therapeutic regimens are highly toxic, leading to severe
immunosuppressive effects which poisons the body and compromises the road towards
remission. In an effort to mitigate these limitations, cancer-targeting approaches are currently
experiencing a renaissance in the translation of new medicines from pre-clinical to bedside use.
Notably, gene therapy has recently gained widespread traction in cancer research in the advent of
the first RNA interference (RNAi) application in humans. RNAi solicits the use of a doublestranded RNA substrate, aptly named short-interfering RNA (siRNA), which binds to and
triggers the degradation of a targeted complementary mRNA strand within the catalytic site of a
protein complex named, the RNA-Induced Silencing Complex (RISC). In this manner, malignant
mRNA expression is silenced, thereby inhibiting the translation of proteins that can lead to the
production of pathological disorders such as cancer. In spite of their utility, several challenges
still remain towards the development of a fruitful cancer-targeting gene therapy approach. For
example, native siRNAs are plagued by poor pharmacokinetic properties which limit their
therapeutic index and utility in clinical applications.
In this thesis, a new class of siRNA motifs is presented to increase substrate efficacy in
the RNAi application. Our biological target is a member of the heat shock family of chaperone
proteins, the Glucose Regulated Protein of 78 kilodaltons (GRP78) which signals tumor
initiation, proliferation and resistance towards chemotherapy. Moreover, GRP78 is
iv

overexpressed and cell surface localized on a wide range of resilient tumor types but not on
healthy cells, making it a viable bio-marker for the development of the proposed cancer-targeting
gene therapy approach.
Significantly, an efficient solid-phase synthesis method is described in Chapter 2 for the
production of linear, V-shape, Y-branch and
novel V-shape, Y-branch and

hyperbranch GRP78-silencing siRNAs. The

hyperbranch motifs were then studied by CD spectroscopy and

thermal denaturation experiments (Chapter 3). CD spectroscopy was used to characterize the
requisite A-type double-stranded RNA helix for RNAi application; whereas thermal denaturation
experiments were used to validate siRNA hybrid stabilities. With stable siRNA hybrids in hand,
their biological activity was next assessed in HepG2 hepatoblastoma cells, which constitutes a
morbid form of pediatric liver cancer and a valid tumor model for studying our GRP78-targeting
strategy. In Chapter 4 of this thesis, the GRP78 silencing activity of the putative branch and
hyperbranch siRNAs is discussed and related to its underlying mechanisms for inducing
apoptosis in cancer. Towards the development of an effective cancer-targeting gene therapy
approach, Chapter 5 highlights preliminary results that showcase the utility of a cancer-targeting
peptide (CTP) to condense and deliver siRNA within cancer cells for therapeutic treatment. The
latter forms the basis of our cancer-targeting gene therapy approach. This thesis represents an
important contribution towards this ultimate goal, in an effort to selectively eradicate some of the
most lethal forms of cancer.
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CHAPTER 1. DISCOVERY AND ANTI-CANCER APPLICATIONS OF
SHORT-INTERFERING RNA (siRNA)
1.1 DISCOVERY OF siRNA AND ITS ROLE IN THE RNA INTERFERENCE (RNAI)
PATHWAY

RNA interference (RNAi) occurs naturally in animal and plant cells for regulating gene
expression into functional proteins for normal cell structure and activity.1 A crucial component to
the RNAi application is the gene-silencing activity of short (18-21 base-pairs) double-stranded
RNA (dsRNA) also known as short-interfering RNA (siRNA). siRNAs are produced naturally
from the enzymatic processing of lengthy dsRNA sequences. Once formed, siRNAs are recruited
into a protein complex referred to as the RNA-Induced Silencing Complex (RISC). A subunit of
this protein complex (Ago2) catalyzes the hydrolytic degradation of a single siRNA strand,
referred to as the sense-strand RNA (ssRNA). The remaining antisense-strand RNA (asRNA)
functions as a template for targeting and binding to a complementary messenger RNA (mRNA)
sequence for down-regulating its gene expression into protein form. In this mechanism, the
asRNA:mRNA hybrid bound within the active site of RISC inhibits ribosome binding and the
assembly of the translational machinery for protein synthesis. Moreover, RISC catalyzes the
degradation of the mRNA strand facilitating the turnover of additional mRNA for potent gene
silencing effects (Figure 1.1).

1

Figure 1.1. RNAi mechanism for silencing mRNA expression.1

The discovery of the RNAi mechanism was accidental, initially dating back to 1990 with
the work of Jorgenson and co-workers in which they attempted to make a ‘super purple’
petunia.2 Following insertion of an extra copy of a ‘purple’ gene targeting the production of
chalcone synthase, the enzyme responsible for the production of the purple pigment anthocyanin
in petunias, only white petunias were discovered. Albeit the mechanism responsible for downregulating gene expression remained unclear, this discovery proved to be the first application of
RNAi. It was not until 1998, when the seminal works of Fire and Mello produced a full
understanding of the RNAi mechanism in the nematode Caenorhabditis Elegans.3 For their
contributions, Fire and Mello were awarded the Nobel Prize in physiology or medicine in 2006.
Shortly after its discovery and characterization, RNAi research has evolved and demonstrated
many fruitful applications of synthetic siRNAs for treating human diseases associated with the
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expression of malignant genes (e.g. metabolic disorders, cancer, gene mutations and deletions
etc.).1
1.2 RNAi IN CANCER
In relation to cancer, a number of siRNAs have demonstrated potent silencing of
oncogene targets and anti-cancer effects in metastatic cell lines and in tumor-bearing animal
models (Table 1.1).4
These include siRNAs targeting the oncogenesis pathways5-14, such as the Ras, Raf, cMyc and HIF genes that are overexpressed in a variety of tumor tissues, including those
associated with ovarian, melanoma and the pancreas. These oncogenes harbor cancer initiation,
proliferation, and angiogenesis that led to the generation of metastatic forms of tumors that were
found to be resilient to chemical and radiation treatments. In these cases, siRNA administration
proved successful in halting the progression of these cancer types while resulting in significant
tumor shrinkage.
The siRNAs targeting the anti-apoptotic factors aim to silence the causative genes in
cancer that are responsible for evading the cell death pathways.15-18 The anti-apoptotic oncogenes
play a pivotal role in cancer cell replication without restriction, which is another hallmark of the
disease.19 siRNAs that may effectively silence the anti-apoptotic genes may lead to the activation
of the cell death effectors (e.g. Caspase 3 and 7) which stimulate the signaling pathways that are
associated with the cell death response (apoptosis).20 For example, B-cell lymphoma 2 (Bcl-2) is
an anti-apoptotic factor that is over expressed in many tumor tissues such as those belonging to
the prostate and has been validated as a therapeutic target for pre-clinical RNAi application.15
Other anti-apoptotic oncogene targets include: Survivin16,17, the Fas-associated death domainlike interleukin-1β-converting enzyme-like inhibitory protein (FLIP) and X-chromosome linked
IA (XIAP)18 have all demonstrated favorable responses to siRNA treatment in cancer cell lines
3

and tumor-bearing animal models. Moreover, down-regulation of Bcl-2 and XIAP with siRNA
treatment sensitized drug-resistant breast cancer cells to Etoposide and Doxorubicin anti-cancer
drugs, illustrating the potential for developing combination strategies involving oncogene and
chemotherapeutics for more potent anti-cancer effects.18
The cell cycle regulators including the retinoblastoma tumor suppressor (Rb) and p53
pathways have been found to play a critical role in disrupting cellular senescence in cancer, the
ability for cells to divide finite times before soliciting the cell death cascade.21 Thus, siRNAs
have been applied for silencing the expression of tumor suppressors and regaining cellular
senescence. These effects have been demonstrated following siRNA treatment of Cyclin B1 and
E6 tumor suppressor genes in cervical and prostate cancers, respectively.22-24 Moreover, potent
anti-cancer effects have also been demonstrated by silencing the human telomerase activity
which has also been found to play a pivotal role in maintaining cellular senescence.25-26
The interaction between the developing cancer cell and the host environment (known as
the tumor microenvironment) facilitates angiogenesis (formation of new blood cells) and tumor
invasion (metastatic growth), another hallmark of cancer.19 These tumor promoting oncogenes
are associated with the vascular endothelial growth factor (VEGF) and chemokine receptor
(CXCR4) among others, and have each been targeted with siRNAs for induction of leukemia,
prostate and breast cancer cell death.27-31
Cancer drug resistance has limited the applications of chemotherapeutic agents in the
treatment of cancer.32 Cancer drug resistance has been partly associated with expression of the
multidrug resistance gene (MDR1). For example, P-glycoprotein (P-gp) functions as a membrane
bound efflux protein, which binds to intracellular drugs and pumps them out of the cell for
limited to inconsequential therapeutic effect.33 Targeting MDR1 with siRNA has sensitized
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cancer cells to chemotherapeutics such as Doxorubicin and Taxol, by eliminating their drug
resistance and inducing cancer cell death.34-35
Table 1.1. RNAi in pre-clinical cancer therapy4
Pathway

Oncogenes

Cancer types

Oncogenesis

Ras

Ovarian5
Mealnoma6

Raf

Melanoma7
Prostrate8
Breast9

BCR-ABL

Chronic myelogenous leukemia (CML)10

Beta catenin

Colon11

c-Myc

Breast carcinoma12

HIF-1

Cervical and colon13
Breast and glioma14

Apoptosis

Bcl-2

Prostate15

Survivin

Esophageal16
Glioma17

Cell cycle regulators

Cell senescence

Tumor-host interactions

Bcl-2 and XIAP

Breast18

E2F4

Prostrate22

E6, E7

Cervical23

Cyclin B1

Cervical24

hTER

Colon and melanoma25

hTERT

Bladder26

VEGF

Ewing’s sarcoma27
Leukemia28

Chemotherapy
resistance

CD31

Prostrate29

RhoA/RhoC

Breast30

CXCR4

Breast31

MDR1

Pancreatic and gastric carcinoma34
Uterine sarcoma35
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In light of the flourishing pre-clinical data, a series of clinical trials have been issued
(Table 1.2).36 This has led to the first human clinical trials for the application of siRNAs in the
treatment of liver cancers.37 In spite of its unlimited potential, few siRNAs have effectively
translated from the pre-clinical to clinical applications raising the unmet need to develop more
potent and efficacious constructs.

Table 1.2. siRNA candidates in oncology clinical trial as of 2012 adapted from Uchino et al36
and ClinicalTrials.gov.

ClinicalTrials.gov
identiﬁer
NCT00499590

Drug

Route

Delivery

Disease

Target

Phase

States

Company

Bevasir
anib
AGN21
1745/
Sirna –
027
ALNRSV01

IVT

Naked
siRNA
Naked
siRNA

Wet AMD

VEGF

III

AMD

VEGF-R1

II

Termi
nated
Termi
nated

Opko
Health
Allergan/
Sirna

Nebuliz
ation

Naked
siRNA

Compl
eted

Alnylam

IVT

Naked
siRNA
Naked
siRNA

RSV
Nucleocaps
id
VEGF

II

II

DME

RTP801

II

Compl
eted
Recrui
ting

Opko
Health, Inc.
Quark
Pharma

Naked
LNA
Electropor
ation

HCV

miR-122

II

NCT01551745
NCT01505166

Bevasir
anib
PF045236
55
miravirs
en
FANG
vaccine

RSV
infection
after
lung
transplantation
DME

Ovarian cancer,
colon cancer

Bi-shRNAFurin and
GM-CSF

II, II

Santaris
Pharma
Gradalis,
Inc.

NCT00802347

I5NP

I/II

SYL040
012

Ophthal
mic
drops

DGF in kidney
transplantation
Glaucoma
and
ocular
hypertension

P53

NCT01227291

IVT

I, II

Compl
eted

Pﬁzer/Quar
k

NCT00716014

PF045236
55
TD101

Adrenergic
receptor
beta-2
siRNA
RTP801

I/II

NCT00725686,
NCT00713518

Naked
siRNA
Naked
siRNA in
ophthalmi
c drops
Naked
siRNA

Compl
eted
Recrui
ting,
Recrui
ting
Recrui
ting
Compl
eted

Intralesi
onal

Naked
siRNA

Pachyonychia
congenita

Ib

Compl
eted

TransDerm
/ IPCC

NCT00882180,
NCT01158079

ALNVSP02

IV

SNALP

Liver
cancer,
solid tumors

Keratin 6a
N171K
mutant
mRNA
KSP
and
VEGF

I, I

Compl
eted

Alnylam

NCT00363714,
NCT00395057

NCT01065935,
NCT00658086
NCT00306904
NCT01445899

NCT01200420

IVT

IVT

SC
Ex
vivo,
Intrader
mal
IV

Wet AMD
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Quark
Pharma
Sylentis

NCT00554359,
NCT00683553

I5NP

IV

Naked
siRNA

AKI for major
cardiovascular
surgery

P53

I, I

NCT01148953

ALNTTR01
CALA
A-01
EZN2968

IV

SNALP
RONDEL

Transthyret
in
RRM2

I

IV

TTR-mediated
amyloidosis
Solid cancer

IV

Naked
LNA

Advanced solid
tumor, lymphoma

HIF-1a

I

Compl
eted

EZN2968
siRNA
in
dendriti
c cells

IV

Naked
LNA
Electropor
ation

Liver metastases

HIF-1a

I

NCI

Metastatic
melanoma

I

NCT01061840

FANG
vaccine

Electropor
ation

Solid tumors

I

Recrui
ting

Gradalis,
Inc.

NCT01064505

QPI1007
Atu027

Ex
vivo,
Intrader
mal
IVT

Immunopro
teasome
subunits
LMP2,
LMP7,
MECL1
Bi-shRNAFurin and
GM-CSF

Recrui
ting
Active

Naked
siRNA
AtuPLEX

Optic atrophy

Caspase-2

I

Active

Advanced
cancer

PKN3

I

Compl
eted

Quark
Pharma
Silence
Therapeuti
cs
Silenseed
Ltd

NCT00689065
NCT00466583

NCT01120288
NCT00672542

NCT00938574

Ex
vivo,
Intrader
mal

IV

solid

I

Compl
eted,
termin
ated
Compl
eted
Active

NCT01188785

siG12D
LODER

EUS
biopsy
needle

LODER
polymer

Pancreatic ductal
adenocarcinoma

KRASG12
D

I

Recrui
ting

NCT01262235

TKM080301
PRO040201

IV

SNALP

Cancer

PLK1

I

IV

SNALP

Hypercholesterol
emia

Apo B

I

Recrui
ting
Termi
nated

NCT00927459

Quark
Pharma

Alnylam
Calando
Pharma
Santaris
Pharma

Duke
University

Tekmira
Tekmira

1.3 LIMITATIONS OF RNAi IN ONCOGENE THERAPY APPLICATIONS
The application of RNAi in clinical oncology is faced with several challenges.4 These
include: poor delivery and cell permeability, immunostimulatory activity, non-selective (offtargeting) gene silencing effects, poor metabolic stability and acute toxicity.38 For example,
elevated immune responses following siRNA treatment were evaluated by the overexpression of
inflammatory markers; interferon (INF) alpha and beta, cytokines such as interleukin-6 and
tumor necrosis factor (TNF) alpha and chemokine induced by Toll-Like Receptors (TLR)
agonists.39 Sequence similarities between the first 11 nucleotides of the antisense siRNA strand
7

and other genes can bring about off-target silencing.40 Moreover, the metabolic stability of the
native siRNAs in biological media is poor, thereby minimizing its therapeutic index. This is
especially the case in all types of RNA applications (vs. DNA) in biology and medicine. RNA
contains a 2’-hydroxyl group which directs intramolecular transesterfication and hydrolysis of
the vicinal phosphodiester bond leading to RNA isomerization and degradation during acidic,
alkaline and enzyme catalyzed conditions (Figure 1.2).41 Direct cellular introduction of siRNAs
results in transient gene silencing effects due to rapid degradation and renal clearance by
endogenous serum ribonucleases (RNases) within 36-48 hours following siRNA transfection.42

Figure 1.2. RNA isomerization and cleavage steps during chemical and enzyme-catalyzed
reactions.
8

Perhaps the most important obstacle to overcome for the clinical application of RNAi is
the aspect of siRNA delivery. siRNAs are negatively charged as a result of their phosphate
diester backbone. Moreover, they are bulky in size compared to small molecules, and
consequently, siRNAs cannot penetrate the cell membrane by conventional diffusion. In order to
facilitate siRNA cellular uptake, (transfection) vectors must have the ability to effectively
condense (package) siRNA and penetrate the amphiphilic lipid bilayer for efficient intracellular
penetration and cytosolic release of siRNA for RNAi action.43 In order to fulfill these criteria,
transfection vectors must: a) be non-toxic and bio-compatible, b) condense siRNA efficiently, c)
prevent siRNA degradation during circulation, d) deliver siRNA to target sites and avoid offtarget gene silencing, e) enhance uptake in cells and endosomal release once cell internalized,
and f) facilitate the release of metabolically stable siRNAs to initiate potent RNAi effects. For
example, in mouse studies, hydrodynamic injections of siRNA into the tail vein achieves the best
RNAi responses (Figure 1.3).44 However, these studies also indicated that the delivered siRNAs
in mice spread to various tissues including the liver and kidneys, resulting in aberrant gene
silencing effects and cytotoxicities.

9

Figure 1.3. Methods of RNAi delivery in vivo.44

Therefore, for safe and effective RNAi applications in humans, several limitations must be
addressed.

1.4 CURRENT METHODS FOR RNAi APPLICATION IN ONCOLOGY
In an effort to address the drawbacks plaguing RNAi in the clinical settings, a series of
improvements have been developed.45 Firstly, the design of the siRNAs have evolved from the
native siRNA sequences (short 18-21 base-pairs dsRNAs) to those which retain important
features for enhanced siRNA stability and activity. These include the 3’-overhang regions which
facilitate the incorporation of phosphate groups at the 5’-ends by intracellular kinases, activating
the siRNAs for assembly into RISC. Moreover, the site specific incorporation of adenosine and
uridine base-pairs facilitates siRNA strand separation within the active site of RISC for mRNA
recruitment and processing activity. Moreover, the site-specific incorporation of modified RNA,
10

namely the 2’-OMe RNA, within the seed region of the antisense siRNA strand have been shown
to improve siRNA metabolic stability while minimizing off-target gene silencing effects and
immunostimulatory activity (Figure 1.4).

Figure 1.4. Design of effective siRNAs for clinical RNAi application43-45

The selected siRNAs are also screened against other gene targets to determine sequence
homology that may lead to off-target gene silencing effects. For example, selected siRNAs (1922 base pairs), are typically rich in guanosine-cytosine (GC) content, to stabilize siRNA duplex
formation while minimizing RNA self-folding or binding to non-specific mRNA targets.46
Computer algorithms such as, AsiDesigner, used in conjunction with BLAST and FASTA may
help design the optimal siRNA candidates.47
The rise and development of automated solid-phase RNA synthesis48 has led to the rapid
production of chemically derived siRNAs (Figure 1.5).49 Chemical siRNA synthesis allows the
incorporation of chemical modification without restriction to alleviate problems associated with
11

poor nuclease resistance, cell permeability, immunostimulatory activity and off-target gene
silencing effects of the native siRNA sequences.38 For example, bio-conjugation of siRNA with
lipophilic molecules such as palmitic acid and cholesterol enables siRNA permeability in HeLa
cells and potent anti-tumor effects in-vivo.50 Chemical modification of the 2’-position of the
ribose sugar has also been shown to enhance resistance against RNase degradation, while
increasing the half-life of modified siRNA in the cytosol leading to a more effective therapeutic
index.40 Modification of the phosphodiester backbone to boranophosphate siRNA has also
translated to beneficial RNAi effects, including gene silencing activity in HeLa cells for up to
one week due to the enhanced metabolic stability of the backbone modified siRNAs.51
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Figure 1.5. Chemically modified siRNAs and their bioconjugation with lipid moieties.38,40,49-51

To realize the full potential of synthetic siRNA in clinical applications of oncology,
effective, bio-compatible and safe means of administration are necessary.4,36,38 Currently,
transfection methods for the tissue penetration and intracellular localization of siRNAs are
divided into two categories; those belonging to the viral and non-viral delivery systems (Figure
1.6).
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Figure 1.6. siRNA transfection methods for triggering RNAi in mammalian cells.4

Viral transduction methods for siRNA gene silencing applications are typically applied
with inoculated viruses whose capsid is filled with the siRNA component for specific
administration at the localized tumor tissue site.52 The viral delivery systems (Table 1.3) are
based on non-pathogenic strains of the Adenovirus, Lentivirus and Herpes Simplex Virus (HSV).
In spite of their promising potential in oncologic gene therapy applications53, viral transduction
methods are still hindered by some serious drawbacks, including those associated with a lack of
tumor-target specificity, low siRNA transfer efficiency, and increased risk of cytotoxicity due to
the infectious potential of the viral carrier.4,52 Consequently, greater attention to non-viral siRNA
transfection methods has gained widespread practice in cancer gene therapy applications.54
Non-viral transfection agents are typically synthetic poly(cationic) amphiphiles that have
the dual bio-activity of condensing siRNA, due to favorable ionic interactions, and penetrating
the cell surface plasma membrane through necessary amphipathic interactions.54 Typically, the
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siRNA:transfection agent internalizes within the cell by budding from the lipid bilayer through
endosome formation and subsequent siRNA release occurs in the cytosol for RNAi activity.55
Since these vectors are synthetic in nature, they have several advantages over viral transduction
agents. These include: low cost and ease of production and quality control, bio-compatibility,
non-immunogenic and non-cytotoxic, and high siRNA uptake and release at the target tissue site
for effective RNAi application.54 Fruitful examples of non-viral transfection agents in siRNA
oncogene therapy include the use of cationic lipids, cell penetrating peptides, cationic polymers,
dendrimers and the cancer-targeting peptides (Table 1.3). Polyethyleneimine, (PEI) is a cationic
polymer that has been used to transfect siRNAs targeting the HER-2 receptor in breast cancer
cells and in tumor-bearing mice with full bioactivity at completely nontoxic concentrations.56 A
poly(ethyleneglycol) PEG-grafted monolamellar liposome in complex with siRNA generates a
stabilized nucleic acid lipid particle, SNALP™, that has been commercialized by Tekmira
Pharmaceuticals for siRNA applications, albeit with limited success due to the poor cell
permeability properties of PEG and accelerated blood clearance in-vivo.57 Poly(cationic)
hyperbranched molecules, dendrimers, such as those belonging to the poly(amidoamines)
(PAMAM) and poly(lysines) have also been utilized as siRNA transfection agents.43 Cell
penetrating peptides (CPPs) containing basic amino acid residues such as His, Lys and Arg have
also been employed as delivery vehicles for siRNA cell internalization in cancer cells types
including HeLa and Neuro2A neuroblastoma cancer cells.58
The application of peptides in siRNA delivery is especially attractive due to the
biological nature of the transfection reagent. These may provide enhanced bio-compatibility and
reduced cytotoxicities relative to the synthetic polymers. Moreover, the rise of automated solidphase peptide synthesis has provided a quick and efficient synthetic alternative for the
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production of biologically active CPPs in bulk quantities (mg-g scales) for in-vivo siRNA
application.59 In spite of their promising potential, CPP and the synthetic poly(cationic) polymers
remain devoid of cancer cell targeting capabilities, thereby dispersing in all tissues leading to
aberrant gene knockdown effects and toxicity.60 In order to overcome this limitation in oncogene
therapy applications, cancer-targeting peptides, CTPs, have been identified through
combinatorial solid-phase peptide synthesis and screening against cancer cell surface receptor
targets61, or by phage display bio-panning methods that have facilitated the identification of short
peptide ligands of tumor cell surface receptors.62 Thus, CTPs have been employed to selectively
deliver cytotoxic anti-cancer drugs and siRNAs for targeted anti-cancer applications.63
Moreover, combination approaches employing anti-cancer drugs and siRNAs targeting cancer
cell surface antigens have demonstrated the most success and promise in translating cancer
therapy from pre-clinical to clinical settings.18,24,37

Table 1.3. siRNA delivery systems in RNAi oncogene therapy as modified from Uchino et al.36
Delivery

Tissue

Route

RNA

Viral vector
Adenovirus

Brain

ICV

AT1a, AT1b shRNA64

Adenovirus

Muscles

IM

Anti-VEGF
cluster65

Lentivirus
Herpes
simplex virus

Brain
Intrastriatal
mHTT shRNA66
Spinal cord
Intraspinal
SOD1 shRNA67
Dorsal root ganglia Injection into the Trpv1 shRNA68
sciatic nerve
Glioma

Non-viral
vector
Oligofectamine Colon cancer
DOTAP
Liver, spleen
LIC-101
Liver metastasis

miRNA

IT

EGFR shRNA69

IP/IV
IV
IV/SC

B-catenin siRNA70
GFP siRNA71
BCL-2 siRNA72
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Ovarian cancer
Glioblastoma

IP/SC
IP/SC

HER-2 siRNA73
PTN siRNA74

Ebola virus
Lung cancer
Melanoma
Ewing’s sarcoma
Prostate/pancreatic

IP/SC
IV
IV
IV
IV

ZEBOV siRNA75
miR-34a/let-776
RRM2 siRNA77
EWS-FLI 1 siRNA78
PKN3 siRNA79

DOTAP,
Melanoma
cholesterol and
PEG

IV

c-Myc/MDM2/VEGF
siRNA and miR-34a80

Atelocollagen

Testicular cancer

IT

HST-1/FGF-4 siRNA81

Osteosarcoma
Prostate cancer
Liver
Brain

IV

PEI
Nanoparticle
SNALP
RONDEL
AtuPLEX

HDI
Carbon
nanotube

IV
Into the
cortex

miR-14382
miR-1683
HBV siRNA84
cerebral Caspase-385

1.5 THESIS OBJECTIVES
In spite of the growing number of siRNA applications in oncology, there remain few
successful examples that have translated from the pre-clinical to clinical settings. Thus, there’s
still an unmet need to develop more potent siRNA constructs and efficacious delivery systems in
oncogene therapy. In an attempt to improve the oncogene silencing efficacy of siRNAs, Chapter
2 describes the semi-automated solid-phase synthesis of linear, branch and hyperbranch siRNAs
targeting Glucose Regulated Protein of 78 kiloDalton (GRP78) expression. GRP78 is a
biological marker in tumors, typically found over-expressed and cell surface localized on a
variety of cancer cell types. The branch siRNA motifs were designed to contain the sense and
antisense strands embedded within the same molecular structure to favor duplex stability. While,
the hyperbranch siRNAs contain multiple siRNA sequences, targeting single or multiple sites of
17

GRP78 mRNA for a synergistic gene silencing effect. The ability to silence multiple oncogene
sites with hyperbranch siRNAs provides a method for rapidly screening oncogene sequences and
enhancing the mRNA silencing effect in our gene therapy strategy. Their synthesis is reliant on
the incorporation of a branch point nucleotide that may direct the chemical synthesis of the
higher-order branch and hyperbranch siRNAs on solid-phase. Methods and characterization data
for the branch point nucleotide and novel GRP78-targeting siRNA sequences are described in
Chapter 2.
Following siRNA synthesis and characterization, Chapter 3 describes their bio-physical
and structural properties. The fruitful application of siRNAs in the RNAi technology is
dependent on the formation of stable siRNA hybrids in aqueous media that can adopt the
prerequisite A-type helix for biological activity. Thermal denaturation and structural studies
using UV-Vis and CD Spectroscopy, respectively, were used to identify the suitability of the
siRNA constructs for the RNAi application. Interestingly, branch and hyperbranch siRNAs
maintained the required hybrid stability and A-type helix for potential RNAi activity.
In collaboration with Brittany Blackman and Christopher Parronchi, MSc and BSc
students researching in the lab of Dr. Allan D. Blake, the RNAi activity of the siRNA constructs
was evaluated in HepG2 liver cancer cells. The siRNAs were found to elicit effective silencing
of GRP78 expression (50-60%) while stimulating modest effects on cancer cell death (~15%).
The biological assays and results are discussed in Chapter 4, which highlights the suitability of
the novel branch and hyperbranch siRNAs in RNAi applications. Attempts to extrapolate their
full anti-cancer potential are also discussed in Chapter 5, by combining the siRNAs with CTPs
targeting cell surface GRP78 expression on HepG2 liver cancer cells. The CTPs described in this
study were made and characterized by Stesha Joseph, a PhD student researching in the lab of Dr.
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David Sabatino. The structural analyses of the CTP:siRNA complexes were partly contributed
by Reeta Yadav, a PhD student researching in the lab of Dr. Uri Samuni, Queens College. Taken
together, these preliminary results will highlight the first steps towards the development of a
fruitful cancer-targeting gene therapy approach.
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION OF LINEAR,
BRANCH AND HYPERBRANCH siRNAs.
2.1 ABSTRACT
A semi-automated solid phase synthesis method is described in this chapter for the rapid
production of linear, branch and hyperbranch siRNAs. The branch and hyperbranch siRNAs are
novel constructs disclosed for the first time in this thesis. These siRNAs were designed to
improve gene silencing efficacy while expanding the scope of siRNA substrates that may trigger
potent RNAi effects in-vivo. Significantly, the siRNAs were selected to target the Glucose
Regulated Protein of 78 kilodalton (GRP78) mRNA for potent oncogene silencing effects in
cancer cells. In this study, a solid phase synthesis method was developed using our Applied
Biosystems™ (ABI) 3400 synthesizer (ABI) to yield a small library (17) of siRNAs. The
siRNAs consisted of linear, V-shape, Y-branch and

hyperbranch motifs, the latter in which

contained multiple siRNAs for synergistic GRP78 silencing effects in a representative tumor cell
line. The various branch siRNAs were generated from either 5’-OLv 2’-or 3’-OMMT ribouridine
phosphoramidite branchpoint nucleotides, to explore the influence of the branchpoint
connectivities on siRNA structure and activity. Furthermore, the incorporation of 2’-OMe inserts
within the siRNA sugar-phosphate backbone is proposed to improve efficacy while retaining
metabolic stability in biological media. These siRNAs were synthesized in good yields (17-83%)
and purities (≥90%) following ion pairing reverse-phase HPLC analysis and purification.
Furthermore, the identities of the siRNAs were confirmed by molecular weight analyses using
electrospray ionization mass spectrometry (ESI-MS, Novatia Inc, Newton PA). Denaturing and
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native PAGE were finally used to respectively ascertain sequence purity and hybridization for
bio-physical, structural studies and RNAi application.
2.2 INTRODUCTION
2.2.1 SOLID PHASE RNA SYNTHESIS
The demand for synthetic siRNA has increased rapidly since the discovery of RNAi in
order to satisfy applications in high-throughput gene screening and sequencing in addition to
gene therapy.1 Consequently, the rise of solid phase RNA synthesis has led to the rapid
production of native and modified siRNAs. At the heart of this synthetic procedure is the use of
an insoluble polymer support, initially composed of a divinylbenzene cross-linked polystyrene
(DVB-PS).2 This solid support was optimized3 and is now composed of controlled pore glass
(CPG) with pore sizes ranging from 500-3000 Ả. The larger pore sizes facilitate the synthesis of
lengthy and complex RNA sequences.4 The CPG is typically derivatized with long chain alkyl
amino (LCAA) groups that facilitate the incorporation of linkers for the attachment of the
starting RNA monomer.3,5 The CPG is typically composed of a 5’-dimethoxytrityl (5’-ODMT)
2’-tert-butyldimethylsilyl (2’-OtBDMS) RNA bound to the succinyl linker LCAA CPG solid
support (Figure 2.1, i). The 5’-ODMT group is acid labile (3% dichloroacetic acid in
dichloromethane) and can be deprotected to determine the loading of RNA on the solid support
by UV-Vis spectrophotometry (Figure 2.1, ii). The loading capacity is also an important
component in dictating synthesis yields and efficiencies, with higher loading supports (i.e. 80100 mol/g) producing more product at the cost of lower synthetic efficiencies.6 The solid
support is used to drive chemical reactions to completion by adding a large excess of reagents,
while facilitating post reaction work-up procedures by simple filtrations and washing steps
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leaving the RNA bound to the solid support. Thus, the solid support is necessary for generating
full length RNA sequences in good crude yields and purities.

Figure 2.1. i. Attachment of a protected RNA monomer on a succinyl linked LCAA-CPG. ii.
Equation for determining the loading capacity (µmol/g) of RNA monomer attached to the solid
support using UV-Vis spectrophotometry.

2.2.2 RNA PHOSPHORAMIDITES FOR SOLID PHASE RNA SYNTHESIS
The conventional RNA building blocks for automated solid phase synthesis are
composed of an acid labile 5’-ODMT group, base sensitive protecting groups masking the
exocyclic amines (e.g. N-Bz, N-Ac, N-iBu) on the nucleobases, a fluoride labile 2’-OtBDMS
protecting group and a 3’-phosphoramidite which facilitates coupling reactions to the nascent
support-bound RNA (Figure 2.2).7 Although these building blocks are most commonly used in
the production of siRNAs and their analogs (as exemplified in this study), 31 they remain limited
in the production of lengthy, bio-active RNA (>80 nucleotides).8,9 This limitation is primarily
attributed to the chemical nature of the bulky 2’-OTBDMS groups, which sterically hinders the
coupling of the 3’-phosphoramidites leading to the concomitant formation of short failure
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sequences that diminishes yields and purities. For this reason, a variety of 2’-protecting groups
have been developed for ameliorating the solid phase synthesis of lengthy and complex RNA. 10
As a best case example, a 110 nucleotide-long precursor mi-RNA has been produced with the
use of the 2’-O-cyanoethoxymethyl (CEM) RNA phosphoramidite building blocks to provide 1.0
mg (5.5% yield) of pure RNA product.11

Figure 2.2. Structures of commercially available (Chemgenes Inc., Wilmington MA) RNA
phosphoramidites and their protecting groups for automated solid phase RNA synthesis.

2.2.3 AUTOMATED SOLID PHASE RNA SYNTHESIS
The phosphoramidite RNA building blocks were instrumental to the development of the
first automated solid phase synthesis of RNA, founded by Ogilvie and co-workers at McGill
University during the 1980s.12 The introduction of the gene machine has ushered the rapid
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production of small (microgram to milligram) and large (gram to kilogram) quantities of RNA
for applications in biology and medicine.13
The automated solid phase RNA synthesis cycle (Scheme 2.1) begins with a detritylation
step, for the removal of the 5’-DMT group from the RNA monomer linked to the CPG support
(Figure 2.1, i). The detritylation step is performed with a 90 second delivery of 3%
dichloroacetic acid in dichloromethane, 3% DCA: DCM, followed by a DCM wash cycle to
remove any residual DCA prior to the coupling reaction. The RNA phosphoramidites (Figure
2.2, 2.2) are dissolved as 0.15 M solutions in anhydrous acetonitrile, MeCN, and mixed with a
coupling reagent, 0.25 M 5-ethylthiotetrazole, ETT, in MeCN, for reaction with the supportbound RNA. Typically, the coupling reaction for RNA synthesis takes place in 10 minutes (15
minutes for riboguanosine due to the bulky protecting groups). The dinucleotide bound support is
then washed with MeCN to remove the excess coupling reagent and phoshoramidite prior to the
‘capping’ step. The capping cycle is performed for 12 seconds with (Cap A: 1:1:8 v/v/v acetic
anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole in tetrahydrofuran) to
prevent side reactions with uncoupled RNA. During the course of the RNA synthesis procedure
this step generates failure sequences; short RNA fragments that must be removed by RNA
purification. Fortunately, each automated synthesis cycle for RNA is optimized to about 97-98%
efficiency, such that the accumulation of failure sequences during synthesis is minimal.
Following capping, an oxidation step for 14 seconds with a 0.02 M oxidant (I2 in 75/20/5 v/v/v
tetrahydrofuran/ pyridine/ water) converts the reactive phosphite triester to the more stable
phosphate triester backbone. The support is then washed and dried with MeCN and argon prior
to 5’-detritylation and continuation of the synthesis cycle until the desired sequence has been
completed. Following synthesis, RNA is cleaved from the solid support and deprotected using
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alkaline conditions, 1: 1 v/v ammonium hydroxide: methylamine (1: 1 AMA) for 10 minutes at
65 oC. RNA sequences that contain the more resilient protecting groups (i.e. Gua N-iBu) require
lengthier deprotection times, typically accomplished with 3 : 1 v/v ammonium hydroxide in
ethanol (3 : 1 NH4OH:EtOH) for 16 hours at 55 oC. The alkaline solution is volatile and is
evaporated on a Speedvac® concentrator. The crude RNA can be recovered from the CPG using
autoclaved distilled water. The RNA is then concentrated and treated with a 1:1 v/v
dimethylsulfoxide:triethylamine trihydrofluoride (1:1 DMSO:TREAT.3HF, 125 µL) to complete
the 2’-desilylation reaction at 65 °C for 90 min. Following reaction, RNA is precipitated from
the mixture using 3 M NaOAc (25 µL) in n-BuOH (1 mL), isolated by centrifugation and redissolved in autoclaved water for analyses and purification using anion exchange, AE, or reverse
phase, RP, HPLC and with polyacrylamide gel electrophoresis, PAGE.
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Scheme 2.1. Automated solid phase RNA synthesis cycle.
2.2.4 ANALYSIS AND PURIFICATION OF SYNTHETIC RNA BY HPLC
High Performance Liquid Chromatography (HPLC) is commonly implicated in RNA
analysis and purification. This includes denaturing (single-strand RNA) and non-denaturing
(double-strand siRNA) methods using anion exchange20 (AE) and ion pairing reverse phase21 (IP
RP) HPLC.
AE HPLC relies on the separation of RNA based on favorable ionic interactions between
the negatively charged phosphodiester backbone and the positively charged anion exchange
resin. An eluent system, typically composed of aqueous perchlorate salts (i.e. 1 M NaClO4 or 1
M LiClO4) is used to disrupt the ionic interactions between the RNA and resin, which gradually
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begins to elute the RNA from the column. The lengthier RNA sequences are most retained on
the stationary phase and elute with extended retention times, while the shorter ones with fewer
phosphate groups elute faster on the column. In a typical AE HPLC chromatogram, (Figure 2.3,
a), the shorter RNA sequences (labeled failure sequences) elute prior to the desired RNA product
in crude purities ranging from 70-95%, which is dependent on the nature and length of the
synthesized sequence. Following isolation of the desired RNA product, a desalting step
(Sephadex G-25 size exclusion chromatography) is necessary to remove the salt contaminants
from the purified RNA.
RP HPLC employs a column packed with a non-polar stationary phase (e.g. C18) which
facilitates the separation of RNA based on favorable hydrophobic interactions. In order for this
separation to occur, the anionic RNA phosphodiester backbone must be neutralized by the
mobile phase, typically an ion-pairing agent composed of an organic alkylammonium salt (e.g.
triethylammonium acetate, TEAA). This allows for the hydrophobic RNA nucleobases to
interact with the stationary phase of the column. A combination of ion-pairing buffer in organic
solvent (e.g. MeCN) allows for slow elution and separation of the RNA components in the crude
reaction mixture. A typical IP RP HPLC chromatogram, (Figure 2.3, b), improves the separation
of failure sequences, including the RNAs that have failed to incorporate the final
phosphoramidite during solid phase RNA synthesis. These n-1 failure sequences are often
challenging to remove from the desired product. Additionally, the incorporation of an extra
phosphoramidite or incomplete deprotection may also result in the appearance of longer (n+1)
sequences. In this case, IP RP HPLC may allow for better separation and purity of the targeted
RNA sequence relative to AE HPLC (Figure 2.3). Furthermore, the eluent system in IP RP
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HPLC is volatile, facilitating sample concentration and isolation of pure RNA for
characterization.

A

B
[n-1]

Failure sequences

[n+1]

Figure 2.3. AE and IP RP HPLC analysis of RNA. Representative chromatograms of (A) AE
and (B) IP RP HPLC analysis of RNA showing the failure sequences eluting first followed by
the desired RNA and n+1 sequences resulting from incomplete deprotection or multiple
couplings.20,21

The application of AE and IP RP HPLC in the analysis and purification of single strand
RNA is accomplished at elevated temperatures (~60 oC). These conditions denature the Hbonding interactions that are responsible for RNA secondary structures. Interestingly, IP RP
HPLC has been commonly applied for the analysis and purification of double-stranded siRNA.21
In this case, IP RP HPLC conditions are performed at ambient temperatures (~22 oC) that
maintain the integrity of the siRNA duplex structure (Figure 2.4). These methods are widely
applicable for the analysis and purification of siRNA at a detection wavelength of 260 nm.
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Figure 2.4. IP RP HPLC analysis of a double stranded siRNA eluted on a Waters C18 reverse
phase column with eluent gradient from 35-85% B in 10 minutes, 0.2 mL/min, 20 oC. With
solvent A: 100 mM TEAA pH 7 and B: 20% MeCN in 100 mM TEAA pH 7. Detection at 260
nm.21

2.2.5 ANALYSIS AND PURIFICATION OF SYNTHETIC RNA BY PAGE
Gel electrophoresis has been applied for the analysis and separation of medium length (5
-25 nucleotides) to lengthy (>30 nucleotides) RNA.22 In this technique, RNA samples (0.05 –
0.30 O.D. units for analytical and 5.0-15 O.D. units for preparative gel electrophoresis) are
suspended in a gel loading buffer that either retains (sucrose) or denatures (formamide) RNA
secondary structures. A 10-20% polyacrylamide gel is typically used in the analyses of lengthy
RNA (> 80 nucleotides) whereas a 20-24% gel is most commonly used in the separation and
purification of siRNA (18-21 nucleotides). A native polyacrylamide gel electrophoresis (PAGE)
is used to track the formation of RNA structures (in this case double-stranded siRNAs) or the
binding interaction between ligand and RNA.23 For example, a poly(arginine) peptide sequence
was added to siRNA and native PAGE was used to track the optimal stoichiometric ratios for
complex formation (Figure 2.5, i).24 Alternatively, a denaturing PAGE uses urea in the gel
matrix to help denature non-covalent bonding interactions. This facilitates the migration of RNA
across an electric field generated from an applied voltage and current. This result in efficient
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separation of crude samples for analysis and purification.25 The trend for RNA separation on
PAGE is based on size, shape and charge, with the lengthier RNA sequences most retained and
the shorter ones migrating at a faster rate (Figure 2.5, ii). Following electrophoresis, RNA may
be visualized under UV shadowing (260 nm) or with the addition of an intercalating dye such as
ethidium bromide, which makes a purple colored complex with RNA. For preparative PAGE, the
desired RNA band is excised from the gel, transferred to a sterile tube and extracted in
autoclaved water. Typical gel recoveries range from 40-60% and require an additional desalting
step (Sephadex G-25 size exclusion chromatography) prior to mass spectrometry, structure
analyses and biological studies.

Figure 2.5. Polyacylamide gel electrophoresis of i. siRNA:poly(arginine) complexes under
native conditions, 20% polyacrylamide gel with ethidium bromide staining and ii. Crude RNA
analysis using denaturing conditions, 24% polyacrylamide gel using 7 M urea and RNA
visualization at 260 nm.22-25

2.2.6 CHARACTERIZATION OF SYNTHETIC RNA BY MASS SPECTROMETRY
Mass spectroscopy (MS) is the most commonly used analytical technique for RNA
characterization by providing mass to charge ratios (m/z) of the observed ions and fragmentation
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patterns. This characterization method is typically coupled with HPLC, providing the basis for
LC/MS analysis and characterization of RNA samples in high-throughput sequences.26 The most
suitable types of MS analyses for RNA characterization provides mild sample ionization with
little fragmentation. These include: electrospray ionization (ESI) and matrix assisted laser
desorption/ionization time of flight (MALDI-TOF) mass spectrometry.27,28 MALDI-TOF MS
requires the RNA sample to be embedded within a suitable matrix, typically composed of azathiothymine/spermine and L-fucose, which is then subjected to a UV laser beam causing sample
absorption, followed by desorption from the matrix and ionization.29 The ions are then separated
and detected by the TOF-MS producing a mass spectrum of the RNA sample in positive
(protonated) or negative (deprotonated) mode. MALDI-TOF MS is a mild ionization method that
is perfectly suitable for the target molecular weight detection of large RNA samples (≥300 kDa)
in the pico-femtomolar range.28,29
In ESI MS, RNA samples are dissolved in water (µM solutions) and turned into a fine
spray of charged droplets by a high voltage produced by the ESI source. This desolves the
samples and creates ions that are sorted by a quadrupole mass analyzer and detected by some
type of electron multiplier detector. Typically, an eluent system that facilitate sample ionization
and avoids ion quenching can be used. For example, buffers consisting of triethylamine and
hexafluoroisopropanol (TEA:HFIP) are usually well suited for siRNA LC/MS applications.27

2.2.7 APPLICATIONS OF SYNTHETIC siRNAs AND ANALOGS
The power of automated solid phase RNA synthesis has led to the rapid generation of
siRNAs and analogs for high-throughput screening assays against gene targets and applications
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in gene therapy for fighting human malignancies such as cancer.1 Among the trove of examples
represented in the literature, a few are discussed herein to highlight their significance in
elucidating complex biological process and potentially treating some of the most debilitating
disorders.
Fluorescent tags such as Alexa Fluor 488 and Cy5 have been conjugated to the 3’-ends of
the sense and antisense strands, respectively, by solid phase RNA synthesis. The fluorescently
labeled siRNAs were tracked in live Huh-7 cells with a laser confocal fluorescence microscope,
which displayed real-time images of the siRNAs targeting nuclear 7SK, U6 and cytosolic NS3
mRNA.14 These results demonstrated for the first time a responsive RNAi pathway in the
nucleus of live cells (Figure 2.6).

Figure 2.6. Live cell imaging with fluorescently labeled siRNAs (a: Cy5 labeled siRNA, red >
635 nm b: Alexa Fluor labeled siRNA, green 495-520 nm) in the nucleus (c: DAPI blue dye
stain) of Huh-7 human cells. Figure adapted from reference 14.

Similarly, a single molecule fluorescence resonance energy transfer (FRET) assay was
recently developed to determine the mechanism of Argonaute (Ago) binding and cleavage
activity of a single-stranded siRNA (antisense strand) in complex with a target mRNA strand.15
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The Ago enzyme has been associated with mRNA processing, possessing the ability to
selectively degrade the mRNA component during the RNAi pathway. Despite this knowledge,
the mechanistic and kinetic aspects of Ago binding and cleavage activity of mRNA substrate
remain unclear. In an effort to elucidate the mechanism of Ago activity, an antisense strand was
conjugated with an acceptor Cy5 red (> 635 nm) fluorescent tag; whereas a target mRNA strand
was conjugated with an acceptor Cy3 green (535-635 nm) fluorescent tag and a biotin label for
binding to a streptavidin functionalized quartz slide. The antisense strand was mixed with Ago
and incubated with the target mRNA bound to the solid support. Single molecule images at fixed
time intervals were collected with a fluorescent microscope to determine the mRNA binding and
cleavage activity of the Ago enzyme (Figure 2.7).
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Figure 2.7. Single molecule FRET experiment for determining the mechanism of Ago action
with a target mRNA substrate. a) Conjugation of antisense siRNA strand and target mRNA
strand with fluorescent dyes (Cy 5, red >635 nm, and Cy3, green 535-635 nm) and b)
immobilization of biotin labeled mRNA strand onto a streptavidin functionalized surface for c)
FRET monitoring Ago activity. Figure adapted from reference 15.

The application of synthetic siRNAs in gene therapy has received even greater
recognition, with countless examples being published in the literature on a weekly basis. Among
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these fruitful examples, lipophilic siRNAs (Figure 2.8, 2.3) have been made by solid phase RNA
synthesis and demonstrated effective cellular uptake and gene silencing effects in vivo.16
Furthermore, elaborate combinatorial approaches have also been developed to improve the
efficacy of siRNAs in the RNAi mechanism. A series of reports have demonstrated enhanced
silencing effects of self-assembled RNA containing multiple siRNAs, thereby potently inhibiting
gene expression in a synergistic manner. For example, a reducible disulfide siRNA dimer,
linking an siRNA motif targeting the green fluorescent protein (GFP) and another targeting
vascular endothelial growth factor (VEGF) expression demonstrated enhanced cellular uptake
and gene silencing effects in vitro relative to the monomeric form (Figure 2.8, 2.4).17 A
tripartite-interfering RNA (tiRNA) (Figure 2.8, 2.5) displayed more potent and longer lasting
activity compared to the linear control siRNAs.18 Surprisingly, the self-assembled tiRNA
targeting the Lamin, DBP and TIG3 genes did not require processing into its constituent siRNAs
for gene silencing activity in mammalian cells. Lastly, branch siRNA nanostructures (Figure
2.8, 2.6) displaying multiple substrates for RNAi activity also retained the same trend, soliciting
greater silencing effects relative to the linear siRNA controls.19 These siRNAs effectively
demonstrate that the RNAi mechanism is tolerant of modifications that may lead to more potent
gene silencing effects in vivo.
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Figure 2.8. Modified siRNAs for RNAi application.16-19 a) Lipophilic siRNAs displayed
enhanced cell delivery and gene silencing activity in vivo. b) Dimerized siRNA displayed
enhanced gene knockdown effects relative to the linear siRNA controls. c) tiRNA self-assembled
multiple siRNA sequences for synergistic gene silencing effects. d) siRNA nanostructures
exhibit potent RNAi activity.

2.3 PROJECT OBJECTIVES
Inspired by these methods, this chapter describes the design, solid phase synthesis and
characterization of a new class of siRNA nanostructures (Figure 2.9). Based on the putative
linear siRNA sequences for silencing GRP78 expression in vitro, 2.7; 42 V-shape, 2.8, Y-branch,
2.9, and

hyperbranch, 2.10-2.11, siRNAs are proposed to confer greater siRNA stability

while enhancing its GRP78 silencing effects in cancer cells. In our design, V- and Y-branch
siRNAs were inspired by the use of short hairpin RNA (shRNA) in potent RNAi applications.30
The V- and Y-branch siRNAs described in this chapter contain single branchpoint nucleotides
which combines the sense and antisense strands within single molecular structures (Figure 2.9,
2.8 and 2.9, respectively). These motifs are proposed to maintain more stable hybrid structures
relative to their linear controls. Hyperbranch siRNAs were inspired by combination approaches
(Figure 2.8), which featured the delivery of multiple siRNAs to effect more potent RNAi
activity relative to the linear controls targeting single mRNA expression sites.16-19 The
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hyperbranch siRNAs disclosed in this chapter were designed to contain two siRNA motifs
embedded within the same molecular structure by the branchpoint nucleotides. These sequences
were conceived to target single or double sites of GRP78 oncogene expression in cancer cells
(Figure 2.9, 2.10, 2.11). This chapter highlights an optimized solid phase synthesis method for
their preparation and analytical techniques for characterization. These studies are essential to
obtain pure siRNA samples for their bio-physical properties, structure elucidation and RNAi
application.

Figure 2.9. Structures of siRNAs designed, synthesized and characterized in this study.
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2.4 RESULTS AND DISCUSSION
2.4.1 SYNTHESIS AND CHARACTERIZATION OF BRANCHPOINT NUCLEOTIDES
Branchpoint nucleotides have been incorporated within RNA to generate higher-ordered
and biologically relevant structures, such as those belonging to the branch, hyperbranch and
lariat RNA.31,32 These RNA motifs have been shown to have significant biological activity and
serve as useful probes for exploring the influence of RNA structure on cell biology. For example,
branch and lariat RNA have been synthesized and applied as inhibitors of mRNA splicing events
for potential anti-cancer utility.33 Moreover, we have recently demonstrated that branch and
hyperbranch short-interfering RNA (siRNA) potently silence oncogenic Glucose Regulated
Protein of 78 kilodalton (GRP78) expression leading to cell death activity in HepG2 liver cancer
cells.31
A variety of branch point phosphoramidites have been synthesized in the literature and
some are commercially available. For example, a branch point nucleoside composed of a 5’OMMT N-Bz adenosine 2’,3’-bisphosphoramidite has been made for the solution phase
assembly of symmetrically branched RNA trinucleotides (Figure 2.10, 2.12).34 The same branch
point synthon has been applied for the solid-phase assembly of branch RNA structures, albeit
composed

of

homopolymeric

sequences.35

Orthogonally

protected

branch

point

phosphoramidites have been developed for the preparation of asymmetric branch and
hyperbranch RNA in addition to lariat structures on solid phase.19a,31,32,36 For example, 5’-ODMT
2’-Fpmp, and 2’-OtBDMS branch point phosphoramidites (Figure 2.10, 2.13, 2.14) have been
developed for the solid-phase synthesis of branch DNA/RNA chimeras, referred to as msDNA; a
rare form of genetic material found in some bacteria.37 Although these methods are suitable for
the production of asymmetrically branched oligonucleotides, they lack in their ability to generate
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asymmetric RNA. Towards this goal, acyclic linkers containing orthogonal protecting groups
(Figure 2.10, 2.15) have been marketed for the production of branch and self-assembled RNA.19a
Most recently, the development of 5’-OLv 2’OMMT ribouridine phosphoramidites31,36 and
related analogs32 (Figure 2.10, 2.16, 2.17-2.19) have been employed for the asymmetric solid
phase synthesis of biologically relevant branch, hyperbranch and lariat RNA species. The former
is especially practical for generating lengthy (> 80 nucleotides) biologically active RNA
nanostructures for applications in biology31-33, theranostics38 and supramolecular19 chemistry.
Thus, the branchpoint phosphoramidites containing the 5’-OLv and 2’-OMMT orthogonal
protecting groups are a focal point of the proposed research study (Figure 2.10, 2.16).

Figure 2.10. Branchpoint nucleotide phosphoramidites used in the preparation of branch,
hyperbranch and lariat RNA.19a,31-36

The solution-phase synthesis of branchpoint amidites, 2.16 and 2.24, 5’-O-levulinyl 2’
and 3’-O- monomethyoxytrityl ribouridine phosphoramidites (Scheme 2.2) was completed by a
solution phase synthesis method based on literature precedence.36
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Scheme 2.2. Reaction and Conditions: (i). Lv2O, Novozyme® 435, 1,4-dioxane, 22 oC,
overnight, 80%. (ii). MMT-Cl, AgNO3, THF, pyridine. 22 oC, 3 h, 2.22: 40% and 2.23: 20%,
(iii). Cl-P(OCE)N(iPr)2, Et-N(iPr)2, THF, 22 oC, 3 h, 2.16: 55% and 2.24: 60%.

The solution phase synthesis of branchpoint phosphoramidites, 2.16 and 2.24, was
completed via a 3 step synthesis procedure featuring: (a) chemo-enzymatic 5′-levulination of
ribouridine, (b) tritylation and (c) phosphitylation (Scheme 2.2). The first step entailed the
regioselective chemo-enzymatic 5’-levulination of ribouridine using Novozyme® 435
immobilized on lipase.39 This reaction is preferred over chemical levulination which produces
multiple levulinated products upon treatment of ribouridine with levulinic anhydride and 1,4diazabicyclo[2.2.2]octane (DABCO).40 Instead, the chemo-enzymatic approach produced
selectively the desired 5′-levulinyl ribouridine, 2.21, in 80% yield. With pure product in hand,
2.21, was tritylated using monomethoxytrityl chloride to give both the 2′ and 3′ tritylated
regioisomers (2.22 and 2.23) respectively collected in purified yields of 40% and 20%. The
reaction was found to favor the desired 2′-regioisomer due to the enhanced nucleophilicity of the
2′- over the 3′-hydroxyl.41 The identity of the pure regioisomers was ascertained by NMR, in
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which a COSY correlation cross-peak was used to explicitly assign the 2’ and 3’-hydroxyl
groups (Figure 2.11). The regioisomers, 2.22 and 2.23, were phosphitylated separately to their
branchpoint phosphoramidites in purified yields of 55% and 60%. In this case,

31

P NMR was

used to assess the purity of 5′-Lv 2′-OMMT and 5′-Lv 3′-OMMT ribouridine phosphoramidite
diastereomers, 2.16 and 2.24, respectively (Figure 2.12). These are perfectly suitable for solid
phase RNA synthesis, in which the synthetic method removes the chirality at phosphorous. With
pure branchpoint phosphoramidites in hand, opportunity now exists for developing a solid phase
synthesis procedure for branch and hyperbranch siRNAs.
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a)

2.22

3’H

3’OH

Figure 2.11. The 1H-1H COSY NMR for a) 2.22 and b) 2.23 correlating of the 2’-H with the 2’-OH and
the 3’-H with the 3’-OH signals.
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b)

2’H
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2’OH
2’H

Figure 2.12. 31P NMR spectrum of the branchpoint phosphoramidite
diastereomers, 2.16.

2.16
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2.4.2 SOLID PHASE SYNTHESIS OF BRANCH AND HYPERBRANCH siRNAs.
The siRNA sequences synthesized in this study (Table 2.1) are based on the target
nucleotides for down-regulating Glucose Regulated Protein 78 (GRP78) expression in human
cancer cells.42 An iterative protocol for the solid-phase synthesis of branch and hyperbranch
siRNAs targeting GRP78 oncogenes is next described (Scheme 2.3). This solid phase synthesis
approach entails linear RNA synthesis up to the branchpoint nucleotide 2.16. The next reaction
requires a decyanoethylation step, which liberates the phosphate protecting groups affording a
more stable phosphate diester, 2.27, relative to the triester, 2.26, prior to acid detritylation and
chain extension reactions.37 An additional acetylation step caps the 3’ or 5’-ends of the ‘Vshaped’ RNA molecule, 2.28, and prevents additional coupling reactions by acetylating the
terminal hydroxyl group. A manual delevulination procedure is used to liberate the branchpoint
5′-hydroxyl31,32,36 and the branch siRNA, 2.29, is completed by automated RNA synthesis. This
cycle may be repeated for the generation of hyperbranch siRNA sequences (Table 2.1,
sequences 6, 7, 10, 11, 16, 17). Additionally, this methodology lends itself to the incorporation
of modified nucleic acids such as the 2′-OMe RNAs for improving siRNA pharmacokinetic
properties (Table 2.1, sequences 12-17).42 Moreover, branch and hyperbranch siRNAs consisting
of the branchpoint nucleotide, 2.24, were also synthesized to explore the influence of
branchpoint connectivities on siRNA structure and RNAi activity (Table 2.1, sequences 8-11).
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Scheme 2.3. Solid phase branch RNA synthesis method.
The synthesis of linear GRP78 siRNA sequences (Table 2.1, sequences 1-3) were
accomplished on a 500 Å CPG support. These sequences were prepared as suitable controls, in
order to validate their GRP78 silencing and cancer cell death activity.42 The V-shape and Ybranch siRNAs (Table 2.1, sequences 4-5) necessitated the use of a 1000 Å CPG support, which
led to the first successful isolation of the V-shape (Figure 2.13) and subsequently Y-branch
siRNA. For the solid phase assembly of the hyperbranch siRNAs (Table 2.1, sequences 6-7), an
optimized synthesis method was established with 2000 Å CPG. The synthesis method featured
fast deprotecting RNA amidites (which replace the N-Bz/N-iBu protecting groups for N-Ac, NiPr-Pac), milder oxidant (0.02 M iodine/water/pyridine/THF) and short, pulsating detritylation
steps (60 and 30 sec) with 3% DCA:DCM (Figure 2.14). The anti-parallel orientations of the
complementary siRNAs were maintained by introducing un-natural 2’,3’ and 3’,3’55

phosphodiester linkages at the branchpoint nucleotides, and the use of reverse 5’phosphoramidites.31,32,36,44 Incredibly, these changes led to the successful synthesis of an 86-mer
hyperbranch siRNAs (Table 2.1, sequences 6-7). Following this optimized procedure, the
efficient solid phase synthesis of V-shape, Y-branch and

hyperbranch siRNAs composed

from the branchpoint nucleotide, 2.24, was realized (Table 2.1, sequences 8-11). The 2’-OMe
series proved to be a synthetic challenge due to the mixed sequence compositions. In spite of this
challenge, the 2’-OMe siRNAs (Table 2.1, sequences 12-17) were synthesized in sufficient
yields for structure and biological applications.
Following synthesis, RNA was cleaved from the solid support and deprotected using 1:1
v/v ammonium hydroxide / methylamine for 20 min at 65 oC. The crude samples were suspended
in a mixture of 1:1 v/v dimethylsulfoxide/triethylamine trihydrofluoride for 2 h at 65 oC to
complete the 2’-desilylation reaction. Following post-synthesis work-up conditions siRNAs,
were analyzed and purified by IP RP HPLC and PAGE.

2.4.3 ANALYSIS, PURIFICATION AND CHARACTERIZATION OF siRNAs.
The analysis of crude siRNAs by IP RP HPLC generally demonstrated chromatograms
containing lower molecular weight failure sequences with shorter retention times followed by the
desired siRNAs. The failure sequences for linear siRNAs resulted from incomplete couplings
that were typically held to a minimum (<10%) facilitating sample purification. In the case of the
branch and hyperbranch siRNAs, the failure sequences predominantly consisted of incomplete
couplings at the branchpoint nucleotides. This feature can be attributed to the chemically labile
and sterically encumbered vicinal 2’,3’ or 3’,3’-phosphodiester linkages at the branchpoint
positions.36 These branchpoint connectivities have been found to be especially sensitive to acid
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and base catalyzed hydrolysis at elevated temperatures. This effect diminishes yields and crude
purities (≤50%) for the lengthy branch and hyperbranch siRNAs. In spite of these limitations, our
optimized synthesis protocol affords sufficient quantities of siRNAs for analysis and purification,
yielding pure samples (Figures, 2.13, 2.14) for bio-physical, structure and biological studies.

Figure 2.13. IP RP LC/MS analysis of a pure V-shape siRNA (Table 2.1, sequence 4).
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Figure 2.14. IP RP LC/MS analysis of a pure hyperbranch siRNA (Table 2.1, sequence 7).

With purified sequences in hand, native and denaturing PAGE were conducted in order to
validate siRNA purity and hybridization into double-stranded form (Figure 2.15). Under native
conditions, branch and hyperbranched siRNAs (Table 2.1, 4-11, 14-15) showed slower
electrophoretic mobility and the formation of stable higher-order complexes relative to their
linear controls. Alternatively, under denaturing conditions, most siRNAs migrated as their linear
single-stranded oligonucleotides. Exceptionally, branch and hyperbranch siRNAs (Table 2.1, 411, 14-15) maintained stable higher-order complexes under denaturing conditions, suggesting
stable H-bonding base-pairs between the two complementary strands. These results are not
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entirely surprising, considering RNA hairpins possess thermodynamically more stable folded
structures relative to their linear double-stranded sequences.43

Figure 2.15. Native and denaturing PAGE analyses of siRNAs synthesized in this study. A, C
and E: denaturing (7 M urea) 18% PAGE; B, D and F: native (no urea) 18% PAGE of linear,
branch and hyperbranch siRNAs (Table 2.1 sequences 1-15).
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Table 2.1. Characterization data for the siRNA sequences synthesized in this study.
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a

Sequences 1, 4, 5, 6, 8, 9, 10, and 12 derived from nucleotides 1236-1254 containing the

initiation codon for GRP78 mRNA42; bSequences 2, and 13 derived from nucleotides 1887-1906
of GRP78 mRNA42; cSequence 3 is a non-specific control;

d

Sequences 7, 11, 17 contains

e

sequence derived from 1 and 2; Sequences 4-7 and 14-17 are composed with branchpoint
nucleotide 2.16, sequences 8-11 are composed with branchpoint nucleotide 2.24, and sequences
12-17 have 2’OMe inserts at the underlined positions; fDetermined by IP RP HPLC using 8020% 0.1 mM TEAA in MeCN pH: 7.2 (23 min); hDetermined by UV-Vis spectroscopy;
g

Observed mass (calculated mass) determined by ESI-MS in negative mode (Dr. Mark Hail,

Novatia LLC, Newtown, PA).

2.5 CONCLUSIONS
In conclusion, we have demonstrated the effective synthesis, purification and
characterization of a novel class of siRNA molecules. In this study, branch and hyperbranch
siRNAs were effectively prepared by solid phase RNA synthesis. These sequences were
analyzed and purified by IP RP HPLC and by PAGE. The identities of the pure siRNA samples
were confirmed by molecular weight analyses using ESI-MS (Dr. Mark Hail, Novatia LLC,
Newtown, PA). Interestingly, the branch and hyperbranch siRNAs conferred stable single
molecular hybrid structures as detected by native and denaturing PAGE analyses. These results
effectively leads into the bio-physical and structural properties of the synthetic siRNAs, a focal
point in Chapter 3 of this thesis.
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2.7 EXPERIMENTAL SECTION

2.7.1 GENERAL METHODS
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich and
VWR and used as received. Solid phase oligonucleotides synthesis reagents and materials were
obtained from ChemGenes or Glen Research Inc. and also used without further purification.
HPLC grade solvents for chromatography were purchased from EMI Biosciences. Analytical
thin-layer chromatography (TLC) was performed on aluminum-backed silica gel plates (Merck
60 F254). TLCs were visualized under UV shadowing (260 nm) or staining (10%
H2SO4/MeOH). Compound purification using silica gel chromatography was performed on 230400 mesh silica (Sorbent Technologies). Molecular weights for 2.16, 2.20-2.24 were measured as
direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-source in
positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Nuclear magnetic
resonance spectra (1H,

13

C,

31

P COSY, HMQC NMR) were recorded on an OXFORD NMR

AS500 spectrophotometer. The NMR spectra were obtained at ambient temperature using either
an indirect pulse-field gradient (ID-PFG) or a switchable pulse-field gradient (SW-PFG) probe.
The obtained data was processed using VNMRJ software (version 2.2). The 1H and

13

C

assignments were based on gCOSY and gHMQC NMR correlation experiments.

2.7.2 SYNTHESIS OF THE BRANCHPOINT PHOSPHORAMIDITES, 2.16 AND 2.24
5’-O-levulinyl ribouridine (2.21): Levulinic acid (5.0 mL, 49 mmol) and 1 M N,Ndicyclohexylcarbodiimide (DCC) in dichloromethane (6.6 mL, 40 mmol) were stirred together in
260 mL of anhydrous diethyl ether to generate levulinic anhydride (Lv2O). The reaction was run
at room temperature (22 °C) under N2 atmosphere for 5 hours. The byproduct (DCU) was
69

removed by vacuum filtration and the filtrate was evaporated into viscous oil. In a second flask,
ribouridine (2.15 g, 8.8 mmol) was vacuum dried for 5 hours and flushed with nitrogen before
being suspended in 40 mL of anhydrous dioxane with resin-bound lipase enzyme, Novozyme®
435 (3 g). Crude Lv2O was dissolved in dioxane (160 mL) and added in 20 mL fractions over a
period of one hour to the flask containing the ribouridine and enzyme in dioxane. The chemoenzymatic reaction was run overnight (12-16 h) at 22 °C (room temperature) under N2. The
reaction progress was monitored by TLC (10% MeOH in DCM) which confirmed 100 %
conversion of starting material to product and the appearance of two non-polar product (Rf: 0.48
and 0.35). The resin-bound lipase was filtered, washed (MeOH) and recycled for additional use.
The filtrate was concentrated and purified by silica gel column chromatograpy (5-10 MeOH:
DCM) to isolate the product in 80% yield.
1

H NMR (2.21, 500 MHz, DMSO-d6):  11.32 (1H, bs, NH), 7.62 (1H, d, J = 8.5 Hz, H6), 5.66

(1H, d, J = 7.5 Hz, H5), 5.74 (1H, d, J = 5 Hz, H1’), 4.24 (1H, dd, J = 7.5 Hz, H5’), 4.14 (1H, dd,
J = 12, 7.5 Hz, H5”), 4.06 (1H, t, J = 10 Hz, H2’), 3.95 (1H, bs, H3’), 3.32 (1H, s, H4’), 2.71
(2H, s, Lv CH2), 2.61 (2H, s, Lv CH2), 2.08 (3H, s, Lv CH3); 13C NMR (2.21, 125 MHz, CDCL3d1): 212.1 (CO), 177.4 (CO), 168.3 (CO), 155.8 (CO), 146.0 (C6), 107.2 (C5), 93.84 (C1’),
86.35 (C4’), 77.96 (C2’), 74.97 (C3’), 69.01 (C5’), 42.62 (CH2), 34.76 (CH2), 32.74 (CH3); ESIMS [M+Na]+: Calcd. for C14H18N2O8Na : 364.3, found : 364.0.

5’-O-levulinyl 2’-O-monomethoxytrityl ribouridine (2.22) and 5’-O-levulinyl 3’-Omonomethoxytrityl ribouridine (2.23): A tritylation reaction was conducted using nucleoside
2.21 (2.0 g, 5.8 mmol), monomethoxytrityl chloride, MMT-Cl (2.4 g, 7.77 mmol) and silver
nitrate (1.39 g, 4.50 mmol) which were dried under vacuum overnight before dissolving the
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reagents in pyridine (6.0 mL) under nitrogen at room temperature (22 °C). The reaction was run
for 3 h and tracked by TLC (95:5 CHCl3:MeOH) which confirmed the presence of the 2’ and 3’OMMT regioisomers, Rf (2.22): 0.40 and Rf (2.23): 0.28, respectively. The reaction mixture was
then diluted with ethyl acetate (EtOAc) (60 mL) and washed twice with saturated sodium
bicarbonate (NaHCO3) (60 mL). The organic layer was separated and dried using anhydrous
sodium sulfate (Na2SO4). The solvent was evaporated and the crude product purified by silica gel
column chromatography (96.5:2.5:1 chloroform:methanol:pyridine). The presences of pyridine
in the elution buffer complicated the spotting on TLC, so a TLC plate pre-stained with 10%
sulfuric acid in methanol was used to detect the product by detritylating the yellow colored
MMT+ group. The 5’-O-levulinyl 2’-O-monomethoxytrityl ribouridine, 2.22, eluted first and
was dried as a white foam in yields of 40%. The 5’-O-levulinyl 3’-O-monomethoxytrityl
ribouridine, 2.23, eluted second and was dried to a white foam in yields of 20%. The identity of
the 2’ and 3’-OMMT regioisomers was confirmed by 1H-1H COSY NMR which indicated a
correlation cross-peak between the 3’H and 3’-OH in 2.22 and the 2’H and 2’-OH in 2.23.
1

H NMR (2.22, 500 MHz, DMSO-d6):  11.29 (1H, s, NH), 7.49-6.77 (14H, m, MMT), 7.12

(1H, d, J = 8.5 Hz, H6), 5.91 (1H, d, J = 7 Hz, H1’), 5.43 (1H, dd, J = 8 Hz, H5), 5.18 (1H, d, J =
6 Hz, 3’OH), 4.21 (1H, dd, J = 6.5 Hz, H2’), 4.0 (2H, m, H5’), 3.87 (1H, dd, J = 11.75 Hz, H4’),
3.71 (3H, s, OMe), 3.03 (1H, ddd, J = 1, 4.3, 7 Hz, H3’), 2.68 (2H, t, J = 6.3 Hz, Lv CH2), 2.37
(2H, ddd, J = 7.5 Hz, Lv CH2), 2.08 (3H, s, CH3);

13

C NMR (2.22, 125 MHz, DMSO-d6):

207.3 (Lv CO), 172.4 (Lv CO), 163.4 (C2, CO), 158.9 (C4, CO), 150.9-123.3 (MMT, 19C),
102.9 (C1’), 87.77 (C2’), 82.73 (C3’), 87.29 (C4’), 75.02 (C5’), 70.09 (OMe), 55.42 (CH2),
37.76 (CH2), 29.97 (CH3); ESI-MS [M+Na]+: Calcd. for C34H34N2O9Na : 635.6, found : 635.6.
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1

H NMR (2.23, 500 MHz, DMSO-d6):  9.57 (1H, s, NH), 7.60-6.70 (14H, m, MMT), 6.85 (1H,

d, J = 7.5 Hz, H6), 5.86 (1H, s, H1’), 5.18 (1H, d, J = 7.5 Hz, H5), 5.29 (1H, s, 2’OH), 4.30 (1H,
s, H2’), 4.13 (2H, d, J = 12.5 Hz, H5’, 5”), 3.98 (1H, s, H4’), 3.78 (3H, s, OMe), 3.48 (1H, s,
H3’), 2.70 (2H, m, CH2), 2.41 (2H, m, CH2), 2.15 (3H, s, CH3);

13

C NMR (2.23, 125 MHz,

CDCl3-d1): 207.7 (CO), 172.4 (CO), 163.4 (CO), 159.0 (CO),, 151.5-127.6 (MMT, 19C), 113.5
(C1’), 102.6 (C2’), 91.86 (C5) ,88.21 (C3’), 80.89 (C4’), 74.23 (C5’), 72.39 (OMe), 55.31
(CH2), 37.79 (CH2), 29.70 (CH3); ESI-MS [M+Na]+: Calcd. for C34H34N2O9Na : 635.6, found :
635.6.

5’-O-levulinyl 2’-O-monomethoxytrityl 3’-O-phosphoramidous ribouridine (2.16) and 5’-Olevulinyl 3’-O-monomethoxytrityl 2’-O-phosphoramidous ribouridine (2.24): Each purified,
tritylated nucleoside was reacted separately in a phosphitylation reaction by first drying the
tritylated nucleoside (1.05 g, 1.70 mmol) overnight prior to reaction. Dry tetrahydrofuran (THF)
(15 mL) was added to the nucleoside under a flow of nitrogen and N,N-diisopropylethylamine
(DIPEA) (1.26 mL, 9.70 mmol) and the phosphitylating reagent, Cl-P(OCEt)N(i-Pr)2 (700 µL,
2.95 mmol) was to the flask. The reaction was stirred for 3 h at room temperature and monitored
by TLC (2:1 Hexanes:Ethyl Acetate) until the formation of the phospharmadite diastereomers
were observed, Rf (2.16): 0.50 and Rf (2.24) 0.50. A white precipitate, Cl-+NE(Et)(iPr)2, was also
observed as an indication of reaction completion. Upon reaction completion, EtOAc (60 mL)
was added to the reaction mixture prior to washing twice with saturated NaHCO3 (30 mL). The
organic phase was dried over Na2SO4 and concentrated to a yellowish foam. The crude product
was purified by silica gel chromatography (Hex:EtOAc, 2:1). Products 2.16 and 2.24 were
collected, dried as a white foam in yields of 55% and 60%, respectively.
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P NMR (2.16, 80 MHz, CD3OD-d4):  152.2 and 148.5; ESI-MS [M+Na]+: Calcd. for

31

C43H51N4O10PNa : 837.9, found : 837.4.
P NMR (2.24, 80 MHz, CD3OD-d4):  152.4 and 149.6; ESI-MS [M+Na]+: Calcd. for

31

C43H51N4O10PNa : 837.9, found : 837.4.

2.7.3 SOLID PHASE RNA SYNTHESIS
RNA was synthesized on an automated ABI 3400 synthesizer. Reagents for the synthesis
cycle were as follows: detritylation reagent (3% solution of dichloroacetic acid in
dichloromethane), coupling reagent (0.25 M ethylthiotetrazole in acetonitrile), capping reagent
(Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole
in

tetrahdrofuran),

oxidation

reagent

(0.02

M

iodine

in

75:20:5

v/v/v

tetrahydrofuran:pyridine:water) and acetonitrile wash (Biotech grade purchased from EMI).
Oligonucleotide syntheses were performed on a 1 µmol scale using 500 - 2000 Å LCAA CPG.
RNA phosphoramidites were prepared as 0.2 M solutions in anhydrous acetonitrile with coupling
times of 3 min. For the synthesis of branch RNA, the branchpoint phosphoramidites (2.16 or
2.24) were also prepared as 0.2 M solutions in MeCN and coupled with an extended reaction
time of 15 min.
RNA syntheses were performed using the following synthesis cycle: Detritylation:
Dichloromethane wash (40 sec) followed by delivery of 3% dichloroacetic acid in
dichloromethane (90 sec total) split into pulsated 60 sec, then 30 sec, Coupling: delivery of RNA
phosphoramidites with activator (0.25 M ethylthiotetrazole in acetonitrile), Capping:, delivery of
Cap A and Cap B (12 sec) and Oxidation: delivery of oxidizing solution (0.02 M iodine in
75:20:5 v/v/v tetrahydrofuran:pyridine:water) for 14 sec followed by a wait period of 20 sec.
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Single stranded RNA sequences were extended in the 3’5’ orientation on solid-phase until
completion.
Branch and hyperbranch siRNA sequences (4-7, 14-17) and (8-11) were first grown in
the 3’5’ position followed by coupling of the branchpoint phosphoramidite (2.16) and (2.24)
respectively. The branchpoint phosphoramidite was coupled for 15 min, followed by a manual
decyanoethylation step (2:3 v/v triethylamine:acetonitrile, 90 min) prior to the 2’-OMMT
detritylation. The oligonucleotide bound CPG was washed with acetonitrile (30 mL) and
replaced on the synthesizer to complete 3’5’ RNA synthesis of the antiparallel complimentary
strand. The terminal 5’-OH was then capped with automated delivery of Cap A and Cap B (12
sec). Following siRNA synthesis, the 5’-levulinyl protecting group was removed by flushing the
column with 0.5 M hydrazine hydrate buffered in 3:2 v/v pyridine:acetic acid (20 min).
Following delevulination, the CPG-bound 4, 8, and 14 are cleaved and deprotected from the
solid support for analysis and purification. For constructs (5-7, 9-11, 15-17) automated branch
RNA synthesis was continued from the branchpoint 5’-OH. For hyperbranch sequences (6, 7, 10,
11, 16 and 17) an additional branch point phosphoramidite was coupled to the support-bound
branch siRNA (5), and continued as previously described. In the case of hyperbranch siRNAs (6,
7, 10, 11, 16 and 17) reverse RNA phosphoramidites (Chemgenes Inc.) were incorporated to
maintain the antiparallel duplex siRNA orientation.

2.7.4 CLEAVAGE AND DEPROTECTION OF RNA
Cleavage and deprotection of the synthesized RNA was performed after drying the
synthesizer columns under Ar(g) for 10 min. CPG-bound RNA was then transferred into
autoclaved screw-cap microtubes (1.5 mL) and treated with a 1 mL solution of 1:1 v/v
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ammonium hydroxide/methylamine (AMA) (for UltraFast TBDMS RNA phosphoramidites,
Glen Research Inc.) deprotection and heated at 65 °C for 10 min or standard RNA TBDMS
phosphoramidites were treated with 3:1 v/v ammonium hydroxide in absolute ethanol at 55 oC
for 16 to 20 hours. RNA samples were then evaporated in-vacuo and the CPG was washed twice
with autoclaved distilled water (500 µL). Crude oligonucleotides were re-suspended in a mixture
of 1:1 v/v dimethylsulfoxide:triethylamine trihydrofluoride (125 µL) to complete the 2’desilylation reaction at 65 °C for 90 min. The crude RNA samples were subsequently
precipitated from the reaction mixture with 3 M NaOAc (25 µL) in n-BuOH (1 mL).
Precipitation was completed on dry ice for 1 h prior to centrifugation (12 000 rpm) leaving the
crude oligonucleotides as a solid white pellet. For DMT-ON RNA purification, immediately after
desilylation, samples were cooled to room temperature followed by addition of 1.75 mL of
quenching buffer (Glen Research Inc). The quenched RNA samples were transferred to Glen-Pak
RNA cartridges and purified according to the manufacturer’s protocol. The collected RNA
samples were dried in a Speedvac concentrator and re-suspended in autoclaved water (1 mL) for
yield determination using UV absorbance measurements at 260 nm.

2.7.5 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
siRNA samples (1-17) were analyzed using denaturing PAGE. Analytical samples were
prepared by drying 0.1 OD (A260) overnight and re-suspending the sample in a denaturing
formamide solution (80% formamide in 10X TBE buffer) prior to loading on the gel. Samples
were loaded (20 µL/well) along with dye solution (5 µL of 10 mL formamide mixed with trace
amounts of bromophenol blue and xylene cyanol) to track gel migration. The gels were run at
500 V in 1X TBE running buffer on a 7 M urea (21 g), 18% polyacrylamide gel (acrylamide and
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N,N-methylene bisacrylamide, 22.5 mL), prepared using 10x TBE buffer solution (5 mL)
[tris(hydroxymethyl)aminomethane

(TRIS)

(54.5

g),

boric

acid

(27.8

g)

and

ethylenediaminetetracetic acid (EDTA) (1.86 g) in autoclaved water (500 mL), pH 8] for 2 -3
hours. Gels were visualized under short range (265 nm) UV-shadowing and subsequently placed
in a Stains-All® (Sigma) solution (25 mg Stains-All®, 50 mL isopropyl alcohol, 25 mL
formamide, 125 mL water). After 2 h, the gel was removed from the stain solution and exposed
to light for analyses.
For purification, branch and hyperbranch samples (4-7) were prepared using >6.0 OD (A260).
Samples were loaded with formamide (150 µL) and run at 500 V in 1X TBE running buffer until
completion (2 -3 h). Desired product bands were excised from gel and incubated in 1 mL of
autoclaved water overnight at 22 °C to complete the extraction of RNA from the gel. RNA was
desalted using NAP-10 Sephadex G-25 (Illustra™) according to the manufacture’s protocol and
quantified using UV-Vis spectroscopy at 260 nm.
Pure siRNAs (1-17) were analyzed by native PAGE. Samples were prepared by hybridizing
stoichiometric quantities (0.5 nmol) of complimentary single strands in 20 µL of 1X TAE buffer
(40 mM Tris, 20 mM acetic acid, and 1 mM EDTA pH 8.0) and 5 µL of 30% sucrose solution in
1X TAE buffer. Branch and hyperbranch oligonucleotide (0.1 – 0.2 µM) were directly dissolved
in 30% sucrose loading buffer (30% sucrose in 5X TAE buffer). All samples were heated at 95
°C for 5 min cooled to room temperature over 1 h and stored at 4 °C overnight. A 18% native
PAGE was prepared using 5 mL of 10X TBE buffer, 22.5 mL (acrylamide and N,N-methylene
bisacrylamide) and 22.5 mL of autocalved water. Gel was run at 500 V for 2.5 h and visualized
under UV shadowing at 260 nm.
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2.7.6 ION PAIRING REVERSE PHASE HPLC (IP RP HPLC)
All samples (1-17) were analyzed by IP RP HPLC to determine purity. HPLC was
performed on a Waters® 2695 Alliance Separations Module. Crude samples were dissolved in
autoclaved water (0.1 OD for analytical) and injected into a Waters Symmetry C-18 reverse
phase column (4.6 x 150 mm, 5 µm particle size, 120 Å) using a gradient of 10-95% (20%
acetonitrile in 0.1 M triethylammnonium acetate) at 60 oC with a flow rate of 1 mL/min over 23
min at 260 nm. Peak areas were calculated to determine percent purity of samples. IP RP HPLC
was used to confirm siRNA purities>90% following purification.

2.7.7 MASS SPECTROMETRY
siRNA samples (0.1-0.4 µM) were dissolved in autoclaved water and analyzed by mass
spectrometry. Samples were analyzed by Dr. Mark Hail at Novatia LLC, Newton, PA, utilizing
Oligo HTCS equipped ESI/MS in negative mode. The data was obtained and deconvoluted using
ProMass software. Theoretical molecular weights were calculated by entering each sequence on
IDT

website

OligoAnalyzer

3.1

or

on

Mongo

http://www.idtdna.com/analyzer/Applications/OligoAnalyzer,
mdb.cas.albany.edu/RNAmods/rnamass.htm respectively.
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and

analyzing
or

the

sequence;
http://rna-

CHAPTER 3. STRUCTURE AND BIOPHYSICAL STUDIES OF siRNAs
3.1 ABSTRACT
Methods for characterizing siRNA structure and biophysical properties are highlighted in this
chapter. Specifically, Circular Dichroism (CD) spectroscopy was used to investigate siRNA
secondary structure in physiological conditions. Linear, branch and hyperbranch siRNAs were
all found to exhibit the putative A-type helix, which is the trademark RNA structure associated
with double-stranded RNA sequences. Moreover, thermal denaturation experiments using UVVis spectrophotometry were used to evaluate hybrid stability at 260 nm (% hyperchromicity)
with changes in temperatures (5-90 oC). The melting temperatures at which 50% of the hybrids
dissociates to single-strands (Tm) were used to evaluate the thermal stabilities of the siRNAs.
Branch and hyperbranch siRNAs displayed stable hybrid structures (Tm: 68 - >90 oC) relative to
the linear controls (Tm: 67 - 76 oC), and in some cases were found to contain multiple hybrid-tosingle-strand transitions. These results were found to be consistent with stable unimolecular
RNA hybrids, such as those associated with RNA hairpins and with more complex RNA
structures which contain multiple complementary sequences that can denature at elevated
temperatures. Moreover, the 2’-OMe siRNAs were found to display well defined A-type helical
structures and stable thermal denaturation curves (Tm: >90 oC) relative to the native sequences.
Thus, linear, branch and hyperbranch siRNAs were found to exhibit the pre-requisite hybrid
structures and stabilities for triggering the RNAi response.
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3.2 INTRODUCTION
3.2.1 CD SPECTROSCOPY OF RNA
Circular Dichroism (CD) spectroscopy determines the effects of circularly polarized light
on an asymmetric molecule.1 In this application, unpolarized light from a suitable source (e.g.
Xenon arc lamp) is filtered by a monochromator which selects the wavelengths of interest,
typically in the far UV-region (190 - 310 nm) for biomacromolecules, while minimizing stray
light. The beam is then deflected by mirrors and prisms into a plane polarizer which focuses the
light in the same direction before it passes through a photoelastic modulator. This circular
polarizer produces left and right-handed circularly polarized light. The circularly polarized light
then passes through the sample compartment where it interacts with the analyte and produces a
CD signal (ellipticity) as a function wavelength (Figure 3.1). The interaction between
chromophoric chiral molecules and circularly polarized light has been shown to provide
important structural information of simple asymmetric molecules and more challenging
macromolecules.2 Thus, any conformational change in an asymmetric molecule that can absorb
light can be studied by CD spectroscopy. This technique is especially advantageous for the rapid
structure determination of complex biomacromolecules such as proteins, DNA and RNA.3 This
technique produces very sensitive and well resolved structural characteristics of biological
molecules in dilute solutions (low M concentrations) which mimic physiological conditions,
and thereby providing insight on its biologically active structure. Moreover, a CD analysis is a
relative experiment, in which a CD spectrum of an unknown sample is typically compared with
suitable controls to determine structural differences and similarities between samples. Therefore,
CD spectroscopy is an ideal method for producing quick structural analyses of complex,
biologically active molecules.
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Figure 3.1. CD spectroscopy method and sample analysis.2

Nucleic acids own the ability to absorb circularly polarized light and emit a CD spectrum
contingent on their conformations. This is due to the chiral sugar component and the aromatic
nucleobases that absorbs light strongly in the UV region (260 nm: Ade = 15, 340, Cyt = 7,600,
Gua = 12, 160, Ura = 10, 210) resulting in * transitions.4 In the case of single-stranded
RNA, the CD spectrum depends on the chirality of the sugar-phosphate backbone and the
absorption of the nucleobases, relating their stacking arrangement in solution. For example, the
CD spectrum of the dinucleotide ApA, originates from the chiral adenine-adenine interaction
which projects a CD signature that contains a combination of positive and negative extrema at
260 nm, referred to as exciton bands (Figure 3.2, i).2,5 In comparison, the CD spectrum for
double-stranded RNA is strikingly distinct, featuring a maximum band near 260 nm, a minimum
one near 210 nm and less intense exciton bands in between 290 – 310 nm (Figure 3.2, ii).2,6 This
CD signature corresponds to A-type RNA, which is the canonical double-stranded RNA
structural motif characterized as an anti-parallel, complementary, right-handed, helical duplex
structure.7
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Figure 3.2. CD Spectra of i. ApA dinucleotide vs. Adenosine and ii. A-type double-stranded
RNA helix.2

The A-type RNA double-stranded helix is pre-organized by a nucleotide sugar pucker
conformation which adopts a Northern or C3’-endo geometry.8 In this conformation, the C3’ and
C5’ carbons lie above the median plane defined by C1’-O4’-C4’ such that the C5’-C3’-phosphate
diester bond distance is reduced to 5.9 Å. This conformational restraint results in a more compact
duplex conformation with 11 base pairs per helical turn and distances between base-pairs along
the helix axis of 2.6 Å. Furthermore, the bases are displaced by 4.5 Å from the parallel helix axis
creating a deep but narrow major groove and shallow but broad minor groove. This
conformation is also stabilized by the O4’-O2’ anomeric effect and the gauche effects of the O2’C2’-C1’-O4’ torsion angles.8 These characteristics generate the geometric parameters found in ARNA duplexes (Figure 3.3).9
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Figure 3.3. The global helical conformation of A-RNA and its preferred sugar conformation.
Structures and data adapted from reference 9.

Considering siRNA encompass a class of short (18-21 nucleotides) double-stranded
RNA, CD spectroscopy is perfectly suitable for studying the structures of native and modified
sequences. The A-form RNA geometry is a pre-requisite for siRNA binding to RISC and for
stimulating RNAi activity. Moreover, the incorporation of modified nucleic acids have been
shown to improve the pharmacokinetic properties of the siRNAs, while instilling more potent
gene silencing effects. For example, the selective incorporation of 2’-OMe RNA was found to
reduce toxic ‘off-target’ gene silencing effects.10 Meanwhile, the incorporation of 2’-deoxy-2’fluoro-4’-thioarabinouridine (4’-S-FAU) within siRNA was shown to maintain A-type RNA
structure while triggering RNAi activity targeting the firefly luciferase gene.11
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3.2.2 UV-VIS SPECTROSCOPY OF RNA
UV-Vis (absorption) spectroscopy measures the interaction of light in the near UV (190 –
400 nm) to visible region (400 – 800 nm) with a suitable chromophore.12 The chromophore is
typically a conjugated molecule (e.g. aromatic) owning the ability to absorb light and inducing
an electronic transition from a ground to excited state (e.g. *). The absorption of light by
the sample at a given wavelength produces an absorption spectrum.
UV-Vis spectrophotometers12 are equipped with two light sources, typically a deuterium
lamp for the UV region and a tungsten-halogen lamp for the visible region. The light source
passes through a monochromator which focuses the beam of light onto the sample. Based on the
molar absorptivity of the sample, concentration of the solution and path length of the cell, light is
absorbed (while some is transmitted) and detected by a photomultiplier or a photodiode detector.
The UV-Vis (absorption) spectrum correlates the absorbance of the solute in a transparent
solvent (e.g. buffer) at a given wavelength (Figure 3.4).

Figure 3.4. Schematic of UV-Vis absorption spectrophotometer.
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UV-Vis (absorption) spectroscopy can correlate the concentration of the sample in solution for
quantitative measurements. Moreover, this method can also provide information on ligandbinding interactions, conformational transitions and thermodynamic properties of complex
biomacromolecules.12
Absorption spectroscopy is particularly well suited for RNA analyses. This is due to the
favorable absorptivities of the nucleobases in the far-UV (210-310 nm) region (260 nm: Ade = 15,
340, Cyt = 7,600, Gua = 12, 160, Ura = 10, 210).4 This property facilitates the quantitative
determination of RNA in solution.12 For example, the optical density (O.D.) measures the
absorption of RNA at 260 nm (A260nm) in 1 mL of buffer and analyzed in a 1 cm path length
cuvette. Stoichiometric measurements can be calculated using the Beer-Lambert law (equation
3.1), which correlates the absorption of the RNA sample at 260 nm (A260nm) with its
concentration (c, mol/L) in solution, the molar absorptivity of the RNA sequence (, Lmol-1cm-1)
and the path length of the cuvette (l, cm).

A260nm =  c l

equation 3.1

Changes in RNA secondary structures can also be monitored by absorption
spectroscopy.13-14 For example, increases in UV absorptivities typically accompanies transitions
from ordered RNA duplexes to random single-stranded forms. This change in hyperchromicity is
associated with the ability for the RNA nucleobases to absorb light strongly as ‘open’ singlestrands vs. ‘closed’ hybrids. Denaturing agents such as formamide, urea and heat have all been
applied to disrupt the Watson-Crick hydrogen bonding interactions between the complementary
strands. The ability to resists hybrid denaturation provides a measurement of hybrid stability.
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This is the case with thermal denaturation experiments, which monitors the % changes in
hyperchromicities at 260 nm with increasing temperatures.13 The melting curve describes a phase
transition for the melting of a duplex to single-stranded form (Figure 3.5). The midpoint of this
curve provides the melting temperature (Tm, oC) at which 50% of the RNA duplex has denatured
to single-stranded form (helix-coil transition). Basically, the higher the melting temperature the
more stable the hybrid structure.

Figure 3.5. Typical melting curve displaying the phase transition from helix-coil at 260 nm with
increasing temperatures.14

Since RNA hybrid thermal stability can be determined from the melting curves, this
experiment may also lead to a thorough thermodynamic analysis of the folded RNA structure. 14
RNA thermal denaturation thus provides the basis for calculating thermodynamic data associated
with this energy driven process. These include: standard free energy changes in hybrid stability
(ΔGo), enthalpy measuring the heat changes during the temperature dependent thermal melt
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(ΔHo) and the entropy gain (ΔSo) during the helix-to-coil transition. These calculations are
thoroughly reviewed elsewhere14, and will not be further discussed in this study.
Stable siRNA hybrids and related analogs have been shown to trigger potent gene
silencing effects. This is especially the case with the site specific incorporations of 2’-OMe RNA
within bio-active siRNA sequences. 2’-OMe RNA stabilizes the requisite C3’-endo sugar pucker
in an A-type helical arrangement due to favorable anomeric and gauche interactions (Figure
3.6).8,15 This effect has been shown to produce effective GRP78 silencing siRNA in HeLa cells.16
Moreover, the 2’-OMe RNA modifications were also found to increase siRNA metabolic
stability leading to extended RNAi activity, while minimizing the silencing of unintended gene
targets which diminishes toxicity.10,16 The latter is a focal point of our study, which aims to
develop potent GRP78 siRNAs for applications in cancer-targeting gene therapy (Chapter 4).

Figure 3.6. Structure and conformation of 2’-OMe RNA
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3.3 CHAPTER OBJECTIVES
The bio-physical and structural studies of linear, branch and hyperbranch siRNAs will be
reported in this chapter. These studies are essential in determining the pre-requisite siRNA
structure for biological activity. In the RNAi pathway, the RNA-Induced Silencing Complex
(RISC) recognizes and binds to an A-type double-stranded RNA helix. This structure has been
found to be the bio-active conformation for high affinity and selective RNA substrate binding to
the active site of RISC.17 Moreover, this protein complex also contains enzymatic activity
associated with RNA hydrolysis.18 Thus, A-form siRNA structure and duplex stability are
necessary requirements for RISC recognition and mRNA cleavage activity in order to stimulate
potent gene silencing effects in vivo. In this chapter a variety of siRNA sequences and motifs
targeting GRP78 mRNA will be studied using CD spectroscopy (structure analyses) and UV-Vis
thermal denaturation (hybrid stability) in order to elucidate their suitability for RNAi application
(Chapter 4).

3.4 RESULTS AND DISCUSSION
3.4.1 CD SPECTROSCOPY OF siRNAs
In order to assess whether the siRNAs described in Chapter 2 of this thesis (Table 2.1,
sequences 1-17) adopt the pre-requisite A-type duplex for RNAi activity, CD spectroscopy1-6
was used to determine their secondary structures relative to single strand controls (Figure 3.7).
Briefly, siRNA samples were prepared by annealing complementary sequences in a
physiologically relevant phosphate buffer (50 µM, 140 mM KCl, 1.0 mM MgCl2, 5.0 mM
Na2HPO4, pH 7.2) prior to structural analyses by CD spectroscopy. Linear GRP78 siRNA16
demonstrated typical CD profiles for A-form helices, displaying small minimum bands at 210
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and 240 nm in addition to a broad maximum between 255-290 nm (Figure 3.7, c, d).6 These
characteristic signatures in the CD spectrum were distinct from the single-strand controls
(Figure 3.7, a, b), which were found to display random coils with weak exciton bands at around
260 nm corresponding to the absorptivities of the nucleobases.2 In the case of the branch and
hyperbranch sequences (Figure 3.7, e-g), the A-type broad maximum and minimum bands were
also observed between 255-290 nm and at 210, 240 nm, respectively, albeit with a decrease in
the amplitudes of molar ellipticities at these characteristic wavelengths. This suggests some of
the branch hybrids may contain varying proportions of random coil. This is not entirely
surprising, considering the branchpoint nucleotide has been found to slightly distort duplex
structure by restricting the complementary strands within a single molecular structure.9
Nevertheless, branch oligonucleotides were found to maintain their putative geometry for
triggering biological activity.9,19 In this case, the branch siRNAs composed of the un-natural
2’,5’- and vicinal 3’,3’-phosphodiesster linkages were found to be particularly un-stable, leading
the hydrolysis of the branchpoint linkages and release of the single strands (Figure 3.7, f).9 In
spite of this change, branch and hyperbranch sequences generally maintained CD signatures that
were consistent with the canonical A-like helical structures. Thermal denaturation experiments
were next conducted to determine the thermal stabilities of the duplex structures.
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Figure 3.7. CD spectroscopy of the siRNA sequences described in this study (Table 2.1).

3.4.2 UV-VIS SPECTROSCOPY OF siRNAs
In order to assess the duplex stabilities of the branch and hyperbranch siRNAs relative
to their linear controls, thermal denaturation experiments were conducted. The siRNAs (Table
2.1, sequences 1-17, 0.10 - 0.40 µM) were prepared as previously described for the CD studies,
by annealing samples in physiological phosphate buffer (140 mM KCl, 1 mM MgCl2, 5 mM
Na2HPO4, pH 7.2) followed by the bio-physical studies using UV-Vis spectroscopy12-14 (Figure
3.8). Linear single stranded RNAs had little or no hyperchromic shifts in the Tm studies (Figure
3.8, a, b). However, once annealed, linear siRNA sequences 1-3, gave characteristic thermal
denaturation curves that were consistent with a helix-to-coil transitions, (Tm: 67 – 72 0C, Figure
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3.8, c). Site specific incorporation of 2’-OMe RNA within the native siRNA sequences 1 and 2,
produced more stable hybrids (ΔTm: +1 and +5 oC, for 12 and 13, respectively) with consistent
changes in hyperchromicities (ΔH: 25-30%) during thermal denaturation (Figure 3.8, c and d).
Branch and hyperbranch sequences, 4-7, exhibited broad thermal denaturation curves suggesting
multiple helix-to-coil transitions (Figure 3.8, e). These results are consistent with those
associated with more complex RNA motifs, from which each helix-to-coil transition may be
measured at a distinct Tm value.20 Moreover, the branch and hyperbranch siRNAs, 4-7, displayed
greater thermal stabilities (Tm: 68 – 89 oC) and enhanced hyperchromicities (%H: 5-35 %)
relative to their linear controls (Tm: 67 - 72 oC and %H: 5-25%). Considering that structurally
related RNA hairpins possess thermodynamically more stable folded structures relative to their
linear double-stranded sequences, the enhanced hybrid stabilities observed for the branch
siRNAs was not unexpected.21 Consistent with the CD data, the branch siRNAs composed of the
un-natural 2’,5’- and vicinal 3’,3’-phosphodiesster linkages were found to be particularly unstable, leading to broad Tm curves that were reminiscent of the linear single strand controls
(Figure 3.8, a and f). Whereas the branch siRNAs composed of the 2’-OMe RNA inserts, 14-17,
(Tm: 75 – 77 and >90 oC, Figure 3.8, g) were found to produce more stable hybrids when
compared to the native branch sequences, 4-7, (Tm: 69 – 89 oC, Figure 3.8, e). This was found to
correlate with literature precedence, which reports that 2’-OMe RNA stabilizes the requisite C3’endo sugar pucker in an A-type helical arrangement due to favorable anomeric and gauche
interactions (Figure 3.6).8,15 These results are also in agreement with the native polyacrylamide
gel electrophoresis (Figure 2.15) and CD spectroscopy (Figure 3.7) data which displayed stable,
higher ordered A-type helical structures for the branch and hyperbranch sequences in comparison
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to the linear double stranded siRNA controls. In light of their enhanced duplex stabilities and Atype helices, branch and hyperbranch siRNAs were next evaluated for RNAi activity (Chapter 4).

Figure 3.8. Thermal denaturation curves of the siRNA sequences described in this study (Table
2.1).

3.5 CONCLUSIONS
In this chapter, siRNA structure and biophysical properties have been validated. CD
spectroscopy was used to confirm the A-type helical geometry for the siRNAs in physiological
buffer. Moreover, thermal denaturation experiments using UV-Vis spectrophotometry revealed
the melting temperatures (Tm) of the siRNAs at 260 nm. In general, branch and hyperbranch
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siRNAs displayed stable hybrid structures (Tm: 68 - >90 oC) relative to the linear controls (Tm: 67
- 76 oC). These results were found to be consistent with those associated with RNA hairpins that
can form stable hybrids from a single molecular structure. Interestingly, short hairpin RNA
(shRNA) have also been implicated in the RNAi response leading to potent gene silencing
effects.22 Moreover, the 2’-OMe siRNAs were found to display well defined A-type helical
structures and stable thermal denaturation curves (Tm: >90 oC) relative to the native sequences.
This highlights their potential utility in stabilizing the canonical siRNA structure for RNAi
activity.10,

16

Exceptionally, the branch siRNAs encompassing the labile 2’,5’- and 3’,3’-

phosphodiester bonds at the branchpoint positions were found to produce unstable hybrids
according to the CD and thermal denaturation data. Thus, linear, branch and hyperbranch
siRNAs were found to generally display the pre-requisite hybrid structures and stabilities for
triggering the RNAi response. The biological activity of the siRNAs synthesized in this study
(Table 2.1, sequences 1-17) will be highlighted in Chapter 4.
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3.7 EXPERIMENTAL SECTION
3.7.1 UV-VIS SPECTROSCOPY
siRNAs (0.1 - 0.5 µM, Table 2.1 sequences 1-17) were annealed in physiological phosphate
buffer (1.0 mL, 140 mM KCl, 1.0 mM MgCl2, 5.0 mM Na2HPO4, pH 7.2) and heated at 95 °C
for 5 min and allowed to cool to room temperature for 1 h and stored at 4 °C overnight prior to
thermal denaturation experiments. Complementary siRNA strands were measured on a CARY
3E, UV-Vis spectrophotometer equipped with a temperature controller monitoring the changes in
hyperchromicities at 260 nm with increasing temperatures (5-95 oC at 0.5 °C/min). Nitrogen was
used to prevent condensation at lower temperatures (<20 oC). The melting temperature (Tm) was
calculated from the first derivative plots of the melting curves, representing the temperature at
which 50% of the duplex has denatured to the corresponding single strands. This data was
exported into an Excel™ spreadsheet for plotting the Tm curves.
3.7.2 CD SPECTROSCOPY
Samples were prepared in similar fashion to the Tm experiments, briefly, siRNAs (0.10 - 0.50
µM, Table 2.1 sequences 1-17) in physiological phosphate buffer, 140 mM KCl, 1.0 mM
MgCl2, 5.0 mM Na2HPO4 pH 7.2. Annealed siRNAs were transferred to fused quartz cells with a
1 cm path length and maintained within the cell holder at 10 °C under N2 for 10 minutes prior to
spectral acquisition. Spectra were collected using a Laurier AVIV 62A DS CD
spectrophotometer as an average of 3 scans with a 1.0 nm band width interval and a 0.5 nm step
interval. Spectra were analyzed between 210 and 310 nm and raw data was processed using J700 Windows® software (version 1.00) and correcting by subtracting the buffer followed by
smoothing the data points. The data was then exported into Windows Excel™ spreadsheet
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software for plotting the CD spectra as changes in molar ellipticities with increasing
wavelengths.
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CHAPTER 4. RNAi ACTIVITY OF GRP78 TARGETING siRNAs
4.1 ABSTRACT
Following successful synthesis, structural and biophysical characterization, the biological
activity of linear, branch and hyperbranch siRNAs is described in this chapter. More specifically,
GRP78 targeting siRNAs were applied for silencing GRP78 mRNA and triggering cancer cell
death within HepG2 hepatoblastoma cells. GRP78 has been classified as a valid molecular target
in cancer therapy due to its implications in cancer initiation, proliferation, metastatic spread and
resistance towards chemotherapeutics. Thus, inhibiting GRP78 function in resilient cancer cell
lines (e.g. HepG2 cancer cells) may serve as an ideal method for overcoming tumor resistance,
thereby providing a breakthrough in the development of more effective anti-cancer treatment
methods. Towards this goal, Lipofectamine™ 2000 was used as the benchmark siRNA cell
delivery (i.e. transfection) reagent in quantities (< 7 g) that did not compromise HepG2 cell
viability. In complex with siRNAs (40 - 80 pmol), potent GRP78 silencing (50 - 70%) was
observed by confocal laser scanning microscopy and western blotting. The branch and
hyperbranch siRNAs (Table 2.1, sequences 4-7) were found to trigger significant GRP78
knockdown (50 - 70%), illustrating their potential as new substrates for silencing oncogene
expression. In spite of their potent GRP78 silencing effects in HepG2 hepatoblastomas, only
modest cancer cell deaths (< 20%) were observed following siRNA treatment (20-80 pmol, 4896 h). These results confirm the suitability of the novel branch and hyperbranch siRNAs in the
RNAi application, but also highlights the resiliency of the HepG2 cells towards GRP78
knockdown. This discovery is not only important to the development of new gene therapy
applications, but also for screening new gene targets that may be implicated in cancer resistance.
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4.2 INTRODUCTION
4.2.1 SELECTION OF GRP78 AS A MOLECULAR TARGET IN CANCER THERAPY
The Glucose Regulated Protein 78 (GRP78) was originally identified from tissue culture
grown in the absence of glucose and resulting in the overexpression of a 78 kilodalton protein.1
GRP78 is also referred to as Bip, due to its ability to bind to the immunoglobulin heavy chains
on pre-B cells.2 GRP78 has since then been characterized as a member of the heat shock family
of chaperone proteins (HSP70), primarily assisting in protein folding events in the lumen of the
endoplasmic reticulum (ER).3 GRP78 activity is stimulated in the presence of physiological ER
stress signaling, typically associated with cell aging, intracellular Ca2+ efflux, glucose
deprivation, hypoxia and the accumulation of misfolded proteins. These signaling pathways have
been extensively reviewed elsewhere4,8, and only a cursory review of GRP78 activity associated
with physiological ER stress signaling will be described herein. In the case of protein misfolding,
the unfolded protein response (UPR) is activated, inhibiting the biosynthesis of additional
proteins and stimulating the activity of chaperone proteins such as GRP78 to assist in protein
folding events.4 In this mechanism, ER stress signaling stimulates the release of free form
GRP78 from protein kinase like ER kinase (PERK), inositol requiring enzyme 1 (IRE1) and
activating transcription factor 6 (ATF6) to unleash the UPR signaling pathway (Figure 4.1).4
This results in PERK-catalyzed phosphorylation of the eukaryotic initiation factor 2 alpha
(eIF2), preventing the translocation of additional proteins in the ER.5 Dimerization of IRE1
stimulates its endoribonuclease activity which splices XPB1 mRNA leading to the expression of
a basic leucine zipper family of transcription factors that assist in the production of chaperone
proteins.5 Similarly, ATF6 is transported to the Golgi where it is cleaved and activated to a
functional transcription factor that aids in the expression of chaperone genes that assists in
protein folding events as part of the UPR signaling pathway.6 In this manner, the UPR functions
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to elevate GRP78 expression levels and activity to release the ER biosynthetic burden in stressed
cells, while allowing them to maintain their functionality for cell survival. Thus, GRP78
functions to inhibit cell apoptosis by rescuing the accumulation of unfolded proteins that may
compromise cell activity, suppress the formation of reactive oxygen species during hypoxia, and
by interfering with caspase activation and caspase mediated cell death.7

Figure 4.1. The many roles of GRP78 in the UPR signaling pathway associated with ER stress.
Figure redrawn from reference 4c.

Moreover, electron microscopy has demonstrated that GRP78 is secreted from the ER to
a variety of intracellular organelles for widespread biological activity (Figure 4.2).8 For
example, GRP78 activity in the perinuclear portion of the ER is also associated with preserving
intracellular Ca2+ homeostasis. In this manner, GRP78 regulates Ca2+ efflux from the ER to the
mitochondria where it functions to stimulate oxidative metabolism for cellular bioenergetics and
survival.9 GRP78 expression and activity have also been observed in the nucleus of the cell,
where it is speculated to play a pivotal role against DNA-damage induced apoptosis.10 Cytosolic
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GRP78 functions to regulate UPR signaling associated with the protein misfolding response,
viral protein assembly and minimizing lead neurotoxicity.11 Interestingly, under ER stress or
pathological conditions, GRP78 is translocated from the ER to the plasma membrane. As such,
cell surface GRP78 has been characterized on rapidly proliferating endothelial, monocytic cells
and tumors, where it behaves as a signaling receptor for cell survival.12 A certain fraction of cell
surface GRP78 may also be secreted extracellularly, where anti-GRP78 antibodies are produced
and can be isolated from the serum.13 The antibodies which bind to the N-terminal domain of
GRP78 have been shown to stimulate cell proliferation and protection against apoptotic events.
Conversely, the selection of C-terminal GRP78 antibodies has been shown to trigger apoptosis.

Figure 4.2. GRP78 cellular localizations and activities. Redrawn from reference 8.
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The cell surface localization of GRP78 in selected cell types associate’s with
physiological stress conditions such as with hypoxia or glucose deprivation and pathological
disorders such as in cancer and metabolic diseases makes GRP78 a potential molecular target for
therapeutic applications. In cancer, cell surface GRP78 signals initiation, proliferation,
metastasis, resistance towards chemotherapy and radiation treatments (Figure 4.3).4,8,14

Figure 4.3. Pluripotent cancer cell surface GRP78 signaling. Redrawn from reference 8.

Although these signaling pathways are extensively described elsewhere4,8,14, a cursory
review is provided in this section to highlight the relevance of GRP78 signaling on
tumorigenesis. In 1-LN prostate cancer cells, GRP78 has been found to act as a receptor for
activated 2-macroglobulin binding which signals the activation of p-21 activated kinase-2
(PAK-2), LIM domain kinase 1 (LIMK1) and cofilin phosphorylation that subsequently
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promotes tumor metastatic spread.15 Moreover, the GRP78-2-macroglobulin binding
interaction also triggers cell survival and proliferation in solid tumors via the AKT and NF-KB
signaling cascade which is activated by phosphorylation with intracellular kinases (e.g. ERK 1/2,
MAPK, Akt, PI3K).16 Cripto, a multifunctional cell surface protein also binds to cell surface
GRP78, enhancing tumor growth by inhibiting transforming growth factor- (TGF-) signaling
activity.17 Moreover, Kringle 5 and Par-4 have also been identified as GRP78 cell surface
binding partners that increase intracellular apoptotic events. The ability for GRP78 to block
apoptosis includes its binding and inactivation of CHOP, BIK and caspase 7, cell death effector
proteins.18 Additionally, GRP78 chemoresistance has been hypothesized by the synergistic
effects of the pro-survival UPR mechanism and cell proliferative effects of the AKT/PI3K
signaling pathway.19 Thus, GRP78 signaling pluripotency enables tumor cell survival and
progression by evading the cell death response or depending on protein partner, increases
apoptosis.
Cell surface GRP78 signaling activity and overexpression have been correlated with a
variety of solid tumors of the urinary, lymphatic, digestive, mammary, cerebral and respiratory
systems, but not in normal tissues (Figure 4.4).4,8,14 For example, the GRP78
immunohistochemical reactivity was found to be significantly higher in prostate cancer and
lymph node metastasis specimens when compared to corresponding benign tissue controls.20
GRP78 levels were also found to be markedly higher in human renal carcinoma21 and in gastric
cancer22 specimens relative to the adjacent non-tumor tissues. Overexpression of GRP78 in
hepatocellular carcinoma promoted tumor invasion in vitro and in vivo due to the activation and
activity of a focal adhesion kinase (FAK) which negatively regulated Rock kinase activity by
promoting the phosphorylation of p190RhoGAP.23 In breast cancer, GRP78 has been found to
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correlate with metastatic spread and resistance towards chemotherapeutic treatments such as
adriamycin, etoposide, taxol and vinblastine.24 The overexpression of GRP78 has also been
found in brain tumors associated with malignant glioma tissues (Figure 4.4). In these cases,
GRP78 activity has been correlated with resistance to chemotherapy and -radiation, induction of
tumor proliferation and a low median survival rate for the patients.25 The same trend has also
been observed in lung26 and melanoma27 tumors, making GRP78 a ubiquitous tumor biomarker
for the development of targeted anti-cancer approaches.

Figure 4.4. Immunohistochemical staining of GRP78 in human glioma tissues and normal brain.
The two cross-sections of peritumoral brain tissues were stained with anti-GRP78 antibody (red)
and blue hematoxylin as background stain.25
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Inhibitors of GRP78 activity have been shown to trigger apoptosis in cancer cells (Figure
4.5). For example, epigallocatechin gallate, (4.1, EGCG), a flavonoid natural product found in
green tea leaves and honokiol, (4.2, HNK), a magnolia grandiflora derivative have been shown to
bind to the GRP78 ATPase domain, induce ER stress leading to potent cell death effects in
melanoma, glioblastoma and neuroblastoma cell lines with and without ER stress inducers
fenretinide or bortezomib.28

In a structure-design based approach, a library of synthetic

adenosine-based inhibitors, targeting the GRP78 ATP binding domain were developed for
structure-activity relationship studies.29 The lead analog, 4.3, retained potent (KD: 60 nM) and
selective GRP78 binding affinity when screened against homologous heat shock proteins.
Verrucosidin (4.4, VCD) a fungal metabolite with putative GRP78 inhibitory activity, was found
to exhibit potent cytotoxic effects in breast cancer cell lines by inhibiting the mitochondrial
energy production.30 This finding has fueled speculation that other supposed GRP78 inhibitors
(e.g. arctigenin, deoxyverrucosidin, efrapeptin, piericidin, pyrvinium, rottlerin, valinomycin)
might also act in a GRP78-independent fashion.30

Figure 4.5. Small molecule inhibitors of GRP78 activity.28-30
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Leading into biopolymer modulators of GRP78 activity, the serine protease subtilase
cytotoxin was used to selectively cleave GRP78, thereby sensitizing apoptosis-resistant cancer
cells to Photofrin-mediated photodynamic therapy (PDT).31 The discovery of a peptide ligand
derived from the cochaperone Bag-1 has been shown to bind to and inhibit the refolding activity
of GRP78 causing apoptosis in in vivo xenograft tumor models.32 Moreover, peptide ligands and
circulating GRP78 antibodies have been identified to selectively bind cell surface GRP78 on
tumor cells, forming the basis for GRP78 tumor-targeting approaches,33 as highlighted in
Chapter 5.
Knockdown of GRP78 has also been shown to sensitize cancer cells to chemotherapy or
radiation treatments resulting in cancer cell death. For example, siRNA-mediated silencing of
GRP78 expression enhanced the cytotoxic effects of fenretinide or bortezomid in CHL-1 and
WM266-4 melanoma cells by two- to three-fold relative to the untransfected controls.27 siRNA
transfection in primary cultures of human brain endothelial cells, derived from the blood vessels
of malignant glioma tissues (TuBEC) reversed chemoresistance to a wide range of anti-cancer
drugs including CPT-11, etoposide and temozolomide.19b Similarly, GRP78 knockdown
enhanced apoptosis in colon cancer DLD-1 cells following treatment with epirubicin. In this
case, GRP78 silencing sensitized the cells to the cytotoxic drug treatment by decreasing
intracellular levels of ROS and survival signaling of the Akt pathway.34 In a similar combination
approach against human urothelial carcinoma cells, GRP78 knockdown potentiated the cytotoxic
effects of celecoxib, a selective cyclooxygenase-2 inhibitor (COX-2).35 It is also worthwhile to
note that while siRNA-mediated knockdown of GRP78 was found to reverse chemoresistance
and enhance the cytotoxic effects of the anti-cancer drugs, silencing of GRP78 is in itself
insufficient to stimulate apoptosis. These results confirms the synergy associated with GRP78

106

activity and cell survival, but also underscores the importance of targeting GRP78 in
combination approaches that abolishes resistance in highly resilient and recurring tumors.

4.3 CHAPTER OBJECTIVES
A novel GRP78 gene-targeting approach is described in this chapter with the use of
linear, V-shape, Y-branch and

hyperbranch siRNAs (Figure 2.9).42 In this study conducted

by Brittany Blackman40 and Christopher Parronchi in collaboration with Dr. Allan Blake
(Department of Biological Sciences, Seton Hall University), siRNAs (Table 2.1, sequence no.
1-7) were treated with Lipofectamine™ 2000 (Invitrogen, CA), and transfected in HepG2 liver
hepatoblastoma cells to explore their biological activity (Figure 4.6). In order to confirm their
suitability for the RNAi application, cell lysates are used to determine the total GRP78 content
with and without siRNA treatment. In this case, western blotting with an anti-GRP78 antibody
and a suitable secondary antibody for detection will be used to determine GRP78 expression
levels in HepG2 cells. Moreover, laser scanning confocal microscopy will be used to monitor
cell surface GRP78 expression levels with and without siRNA treatment. In order to investigate
the anti-cancer activity of the siRNAs, a Trypan blue cell viability assay will be conducted. In
this manner, the novel siRNAs synthesized (Chapter 2) and characterized (Chapter 3) will be
evaluated for anti-cancer application.
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Figure 4.6. GRP78 gene-targeting method with

hyperbranch siRNA:Lipofectamine

complex42

4.4 RESULTS AND DISCUSSION
4.4.1 HepG2 CELL CULTURE
Hepatoblastoma (HB) is an embryonal form of liver cancer often found in the early stages
of childhood.35 HepG2 hepatoblastomas are a relevant tumor cell line model for the pre-clinical
study of pediatric liver diseases.36 The HepG2 cell line (ATCC, CA) is credited to Dr. Barbara
Knowles and colleagues (Wistar Institute, PA) who extracted them from the liver tissue of a 15
year old white male who had developed a well differentiated heptocellular hepatoblastoma back
in 1979.36,37 Moreover, cell surface GRP78 expression has been correlated with tumor invasion in
HepG2 cells making it a clinically relevant tumor model for validating our GRP78-targeting
strategy.38
Based on literature precedence for the HepG2 cell culture37,38, HepG2 liver cancer cells
(~5 x 104 cells) were plated in 24-well culture plates and grown in DMEM with 10% fetal bovine
serum for 48 h in a humidified incubator at 37 C with 5% CO2. Following a 24 h incubation
period, the HepG2 cells were passaged and treated with a basal, serum free medium (OptiMEM)
and incubated for an additional 24 h prior to analyses. Cell counting to discern viability was
performed with a Countess automated cell counter using a Trypan blue exclusion assay. A rich
population of HepG2 cells (50,000 cells/well), were maintained for siRNA transfections.
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4.4.2 siRNA:LIPOFECTAMINE TRANSFECTIONS IN HepG2 CELLS
In order to facilitate cell penetration of the GRP78 targeting siRNAs, a suitable
transfection reagent functions to bind siRNA and mask the negatively charged phosphodiester
bonds for efficient translocation across the negatively charged amphiphilic plasma membrane.
For example, Lipofectamine™ 2000, a cationic amphiphile forms an ionic complex with siRNA
and ushers its delivery across the lipid bilayer for RNAi application. This reagent is the
benchmark transfection agent for delivery of oligonucleotides inside cells.39
Prior to siRNA transfection, the toxicity of Lipofectamine™ 2000 was evaluated within
HepG2 cells to determine a range in which this reagent can be used without triggering cell
cytotoxicities.40 In this toxicity experiment, Lipofectamine™ 2000 (1 µg/well to 10 µg/well) was
administered to the HepG2 cells in a 96-well plate (9 wells/treatment) and incubated for 48 h at
37 C with 5% CO2. Following incubation, a Calcein AM cell viability assay41 was performed to
determine cell viability with and without Lipofectamine treatment (Figure 4.7). In this assay,
only cells treated with higher quantities of Lipofectamine (10 µg) exhibited a significant drop in
cell viability (>50%). Thus, an effective range of Lipofectamine™ 2000 (1-7 µg) can be used for
optimizing the siRNA transfection protocol.
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Figure 4.7. Lipofectamine™ 2000 toxicity on HepG2 cells. HepG2 cells were plated 50,000
cells/well in 96 well plate with 9 wells per treatment with Lipofectamine™ 2000 (0 – 10
µg/well). The number of viable cells/well after Calcein AM treatment is shown (n=1).40,41

In order to test the optimal stoichiometric ratios for the Lipofectamine:siRNA complex to
be used in the transfection experiments, increasing amounts of a linear control GRP78-targeting
siRNA (20 - 80 pmol, Table 2.1, sequence no. 1) were tested with a nominal quantity of
Lipofectamine (1 µg).40 Following transfection, Western blot44 and Trypan blue exclusion45
assays were used to determine the extent of total GRP78 knockdown and HepG2 cell death,
respectively.

The Western blot studies (Figure 4.8) revealed a dose-response relationship

between the siRNA treatment (20 - 80 pmol) and GRP78 silencing (50-60%), illustrating the
effectiveness of the siRNA:Lipofectamine complex in the RNAi application. In spite of these
encouraging results, minimal HepG2 cell death (< 5%) was observed even at the highest siRNA
doses (80 pmol) and extended incubation times (4 days). These results are not surprising,
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considering GRP78 knockdown has been shown to be in itself insufficient for stimulating cell
death,42,43 but however sensitizes cells to chemotherapeutic agents which can trigger
apoptosis.19b,27,34,35,38

A.
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Figure 4.8. Western blot for the siRNA:Lipofectamine transfections. A. Representative western
blot (n=5) with varying concentrations of GRP78-targeting siRNA (20 - 80 pmol, Table 2.1,
sequence no. 1); B. GRP78 protein expression levels quantified using NIH Image J (n=5);
statistical significance was determined by ANOVA (p< 0.05).40,42

From

this

preliminary

study

(Figure

4.8),

optimized

methods

for

the

Lipofectamine:siRNA transfection experiments were developed in HepG2 cells in order to
deduce the influence of the GRP78-targeting siRNA constructs (Table 2.1, sequence no. 1-7) on
RNAi activity.40,42 Briefly, siRNA samples (40 pmol) were transfected with Lipofectamine™
2000 (1 µg) in HepG2 cells (50,000 cells/well), and incubated in OPTIMEM at 37C with 5%
CO2. Following transfection (48 h), cell lysates were prepared (RIPA lysis buffer, Invitrogen)
and resolved by SDS PAGE for immunoblotting with an anti-GRP78 primary antibody and a
secondary antibody conjugated to horseradish peroxidase (HRP). In this assay, total HepG2
cells’ GRP78 expression levels were determined by the redox activity of the
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3,3’,5,5’-

tetramethylbenzidine (TMB) substrate.44,46

The gel (Figure 4.9 A) was analyzed by

autoradiography and demonstrated effective silencing (40-60%) of GRP78 expression by linear
(~40-60%, Table 2.1 sequence no. 1 and 2), V-shape (~50%, Table 2.1 sequence no. 4), Ybranch (~55%, Table 2.1 sequence no. 5) and hyperbranch (~50-60%, sequence no. 6 and 7)
siRNAs (Figure 4.9 B). These results confirms the GRP78-targeting and silencing effects of the
linear siRNA controls (Table 2.1 sequence no. 1 and 2), but also underscores the unprecedented
RNAi activity of the V-shape, Y-branch and

hyperbranch siRNAs.

Cell viability data was also collected following a Trypan blue cell staining assay45, to
establish the extent of HepG2 cell death following GRP78 knockdown. In this assay, GRP78targeting siRNAs (Table 2.1 sequence no. 1-7) stimulated 10-20% HepG2 cell death. The
observed cell death percentages for linear siRNA controls were consistent with those observed in
the literature43, with approximately 5% (1), compared to about 15% with V-shape siRNA (4),
about 10% with Y-branch siRNA (5) and ~15% with

hyperbranch siRNAs (7) (Figure 4.9 C).

Interestingly, hyperbranch siRNA (Table 2.1 sequence no. 7), targeting double sites of GRP78
mRNA exhibited more potent GRP78 knockdown (60% vs. 40%) and cell death (15% vs. 5%)
relative to the linear controls (Table 2.1 sequence no. 1 and 2), highlighting its synergistic
effects in the RNAi application.
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Figure 4.9. Linear, branch and hyperbranch siRNAs transfection results in HepG2 cells. A:
Western blot of HepG2 cells lysates showing GRP78 expression following transfection with
linear (2) and (1+2) siRNA controls and with V-shape (4), branch (5) and hyperbranch siRNAs
(6,7), B: GRP78 expression levels were detected by autoradiography and quantified using NIH
ImageJ, C: Cell viability data determined by Trypan blue exclusion. The data shown are the
mean  SEM for 3 or more experiments, each performed in duplicate and analyzed with
GraphPad Prism 4.0 and statistical significance was determined by ANOVA (p< 0.05).40,42

4.4.3 CELL SURFACE GRP78 EXPRESSION IN HepG2 CELLS
Confocal laser scanning microscopy was used to confirm the presence of cell surface
GRP78 on HepG2 cells with an anti-GRP78 primary and a secondary antibody conjugated to
fluorescein isothiocyanante (FITC).40,42 HepG2 cell images (Figure 4.10) were captured with a
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40X oil objective lens, from which FITC labeled GRP78 stained green and DAPI-stained cell
DNA shone blue (Figure 4.10, A). Cell surface GRP78 knockdown was subsequently assessed
by transfecting the HepG2 cells with Lipofectamine:hyperbranch siRNA (40 pmol, Table 2.1
sequence no. 7) followed by incubation at 37 oC for 48 hours. Following transfection, cells were
plated on glass slides and treated with the same anti-GRP78 primary and FITC-labeled
secondary antibodies to examine GRP78 expression levels (Figure 4.10, B). In this assay,
hyperbranch siRNA 7 potently silenced GRP78 expression (~70% knockdown) as shown by the
minimal ‘yellow’ FITC-signaling relative to the control untransfected cells (Figures 4.10, A C). Moreover, these results also suggest that HepG2 cell GRP78 may be further exploited for the
tumor-targeted delivery of siRNAs (Chapter 5).
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Figure 4.10. Monitoring cell surface GRP78 expression with confocal laser microscopy of A.
paraformaldehyde fixed HepG2 cells with an anti-GRP78 antibody (FITC; green) and DAPI
(blue) nuclear stain. Cells were viewed using a 40X oil objective lens, and the cells are
representative of separate viewing fields from two independent experiments.; B. HepG2 cells
transfected and incubated (48 h) with hyperbranch siRNA (Table 2.1 sequence no. 7), fixed
with 2 % paraformaldehyde and stained with DAPI (blue), and FITC conjugated to GRP78
protein expression (green).; C. Percentage of the HepG2 cells with FITC-GRP78 signal for both
the control and transfected sample. Statistical significance determined with student’s t-test and p
value < 0.05.40,42

4.5 CONCLUSIONS
In this chapter the putative RNAi activity of the GRP78-targeting siRNAs (Table 2.1,
sequence no. 1-7) has been validated in HepG2 hepatoblastomas. The novel V-shape, Y-branch,
and

hyperbranch siRNA motifs (Table 2.1, sequence no. 4-7) were found to solicit potent

GRP78 silencing (50% – 60%). Significantly, hyperbranch siRNA, 7, targeting double sites of
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GRP78 mRNA expression was found to trigger more potent GRP78 knockdown (60% vs. 40%)
and HepG2 cell death (15% vs. 5%) highlighting its synergistic effects relative to the linear
control siRNAs, 1 and 2. This finding is important for the development of new siRNA constructs
that may target multiple genes in a combination approach for improving RNAi efficacy and also
for screening new oncogene targets. Moreover, confocal laser scanning microscopy also
confirmed potent cell surface GRP78 knockdown (~70%) with hyperbranch siRNA, 7.
Interestingly, FITC-labeling of GRP78 on the cell surface of HepG2 cells suggests the possibility
of developing a tumor-targeting approach for the selective delivery of siRNAs in cancer cells.
The latter is a focal point of the final thesis chapter (Chapter 5), which highlights the preliminary
studies towards the development of a cancer-targeting gene therapy approach.
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4.7 EXPERIMENTAL SECTION
4.7.1 HepG2 CELL CULTURE
The human hepatoblastoma, HepG2 cells (American Type Culture Collection,
Manhasset, VA) were cultured in T25 cm2 and T75 cm2 flasks (Grenior Bio-one Cell star, FL) in
Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAX and heat-inactivated 10% Fetal
Bovine Serum (Gibco, CA), containing 1% penicillin/streptomycin (Gibco, CA), in an incubator
set at 37 oC with a humidified atmosphere of 5% CO2. Cells were routinely passaged at 75%
confluence using Dulbecco’s PBS (Gibco, CA) and 0.05% Trypsin-EDTA (1X), Phenol Red
(Gibco, CA) and then split into a 1:10 dish ratio. Cells used in the transfection experiments were
cultured in 6- 96-well culture plates and allowed to recover for 24 hours before treatment.

4.7.2 siRNA PREPARATION
A solution of each single strand siRNA (50 µM) was prepared by taking an aliquot from
the crude stock and adding millipore water to give the required concentration. From these stock
solutions (50 µM), siRNAs (30 µL) were combined in a microcentrifuge tube and treated with
annealing buffer (15 µL of 5X Annealing Buffer: 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5.0
mM EDTA) to give a final volume, 75 µL (20 µM). The solution was then heated at 95 oC (1
min) to denature higher-order structure, centrifuged and allowed to slow cool at room
temperature (1 h) before being placed in the fridge overnight for hybrid formation. The resulting
duplexes were frozen at – 20 oC until use.

4.7.3 siRNA TRANSFECTION IN HepG2 CELLS
HepG2 cells were transfected with the appropriate siRNA, 1-7, (40 pmol) and
Lipofectamine™ 2000 (1 µL) according to the manufacturer’s instructions. Briefly, 5 x 104 cells
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were plated in 24-well culture plates containing DMEM (10% fetal bovine serum) and
maintained for 48 h in a humidified incubator at 37 C with 5% CO2. Twenty four hours prior to
transfection the cells were switched to a basal, serum free medium (OptiMEM). Transfections
were performed with Lipofectamine™ 2000 (1 µL) and the appropriate siRNA, 1-7, (40 pmol
siRNA in 50 µL of OPTIMEM). The siRNA-Lipofectamine complexes were incubated at room
temperature for 20 min, added to the cell monolayers and the plates were incubated at 37 C with
5% CO2. After 24 h, the serum free basal medium was removed and replaced with growth
medium. Transfected cells were harvested 48 h after transfection for analysis.

4.7.4 SDS-PAGE and WESTERN BLOTTING
Parallel cultures of HepG2 cells were prepared with serum-free basal medium (OptiMEM) for 24 h and then incubated in the presence or absence of varying concentrations of
siRNAs (1-7) for 48 hours at 37 ˚C. Cell lysates were prepared with RIPA lysis buffer, heated to
70 ˚C for 10 min., resolved on NuPAGE 10% Bis-Tris gels and electroblotted onto
polyvinyldifluoride (PVDF) membranes. Membranes were treated for 90 min in a blocking
buffer containing 5% (w/v) of non-fat dehydrated milk to minimize non-specific binding. Total
HepG2 cells’ GRP78 expression was immunodetected with a 1:200 final dilution of anti-GRP78
N-20 antibodies. The membrane associated immunoreactivity was then detected using a 1:5000
dilution of a horseradish peroxidase-conjugated anti-goat secondary antibody and detected using
ECL Plus chemiluminescence. The resulting autoradiograph was scanned, quantified with NIH
ImageJ and expressed as integrated pixel density.
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4.7.5 CONFOCAL MICROSCOPY
HepG2 cells were plated at a cell density of 15,000 cells/well on 4 well chamber glass
slides.

Cells were transfected and incubated for an additional 48 hours prior to confocal

microscopy. Cells were then rinsed with Serum free DMEM, and fixed on the glass slides with
2% paraformaldehyde in PBS (Gibco, CA) for 10 minutes. The samples were then blocked in
10% rabbit serum for 30 minutes, incubated in goat-anti human GRP78 N-20 antibody (Santa
Cruz Biotechnology, CA) 1:75 dilution in 2.5% rabbit serum in PBS for 2 hours at room
temperature. After PBS washing the slides were incubated in goat anti-rabbit conjugated with
Fluorescin isothiocyanate (FITC) antibody in 2.5% rabbit serum in PBS for 50 minutes and
Vectorshield (Vector Laboratories, CA) covered to protect from photobleaching. Slides were
counterstained with 4’,6-diamino-2-phenylinode (DAPI) in 0.50 g/mL in PBS for 3 minutes
and then a mounting medium with fluorescence was added with coverslips. Slides were viewed
on a Confocal Laser Scanning Microscope (Olympus, MA) with a 40X oil objective lens in
conjunction with the Olympusview program.

4.7.6 CELL VIABILITY
Cell viability was determined in 24-well plates with HepG2 cells cultured in serum-free
basal medium for 24 h and then incubated in the presence or absence of varying concentrations
of Lipofectamine 2000 (1-10 g) and siRNAs (20-80 pmol, 1-7) for 48 h at 37 o C. The samples
were removed with Enzyme Free Dissociation Buffer (Invitrogen, CA) for 3 minutes at 37 C.
Samples were pelleted and re-suspended in Dulbucco’s PBS (1 mL) and Trypan blue 0.4% stain
(100 µL) was added. Samples were quantified using a Countess automated cell counter
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(Invitrogen, CA). The resulting data was analyzed with GraphPad Prism 4.0 and statistical
significance was determined by ANOVA (p< 0.05).
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CHAPTER 5. PRELMINARY STUDIES TOWARDS THE DEVELOPMENT
OF A CANCER-TARGETING GENE THERAPY APPROACH
5.1 ABSTRACT
Linear, branch and hyperbranch GRP78 siRNAs proved to be valuable substrates for silencing
GRP78 expression (50-70%) and triggering cell death (5-15%) in a HepG2 hepatoblastoma
cancer cell line (Chapter 4). In this chapter, preliminary results which showcase the combination
of GRP78-targeting siRNAs and peptides (i.e. cancer-targeting peptides, CTPs) are described
towards the development of a cancer-targeting gene therapy approach. In this method, linear,
branch and hyperbranch GRP78-silencing siRNAs are complexed with poly(arginine) derived
GRP78-targeting peptides that may usher the selective delivery of siRNAs into GRP78 harboring
tumor cells for RNAi and cell death activity. The complexes formed between the CTPs:siRNAs
were effectively characterized by native PAGE, CD spectroscopy, thermal denaturation, DLS
and TEM experiments which demonstrated the formation of stable, higher-ordered complexes.
Moreover, the direct transfection of a linear GRP78 silencing siRNA (Table 2.1, sequence no.
1) with a CTP derived from the Pep42-R9 sequence demonstrated significant GRP78 silencing
(50-60%) and modest cell death (5-15%) in HepG2 cells which mirrored the results obtained
from the benchmark Lipofectamine:siRNA transfection studies (Chapter 4). These results
suggests that the Pep42-R9 sequence and related CTPs may function as useful GRP78-targeting
transfection agents in a wide range of cancer cell types that display cell surface overexpression
of GRP78. This discovery is important for the development of an effective cancer-targeting gene
therapy approach, which aims to kill cancer cells selectively, while leaving the healthy ones
unscathed.
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5.2 INTRODUCTION
5.2.1 SELECTION OF PEP42 AS A GRP78-TARGETING PEPTIDE
The selection of Pep42, a cyclic peptide composed of CTVALPGGYVRVC was
discovered from a library of short cyclic peptide sequences expressed on the surface of M13
filamentous phage.1 In a process referred to as whole cell phage display biopanning2, the
peptides coated on the phage surface were screened against highly metastatic melanoma cells
(Me6652/4) and a low metastatic clone as control (Me6652/56) for cell binding affinity and
specificity. Following multiple rounds of evolution and selection, phages which strongly
adsorbed on the surface of highly metastatic melanoma cells but not on the low metastatic clone
were isolated and analyzed to determine the identity of the peptide and receptor involved in the
binding interaction.

The corresponding peptide sequence, Pep42, was found to exhibit high

affinity and selective binding to GRP78, even relative to the homologous heat shock protein,
Hsp70, chaperone and the ubiquitous bovine serum albumin, BSA, a surrogate for serum proteins
(Figure 5.1).3
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Figure 5.1. Binding assay of the Pep42 phage with recombinant proteins. Pep42 phage
demonstrates high binding affinity and specificity for GRP78. Figure adapted from reference 3.
The cell surface Pep42:GRP78 binding selectivity was also explored on human cancer
cell lines, including the highly metastatic melanoma cells (Me6652/4), lung adenocarcinoma
cells (A549), osteocarcinoma cells (A549) and HepG2 hepatoblastoma cells relative to two
normal human fibroblast cell lines (HDFa and CCD-11Lu).3 Significantly, FITC-labeled Pep42
was found to bind to the human cancer cells but not the normal cell line controls according to
flow cytometry. The same observation was also noticed with the FITC-labeled monoclonal
antibody specific for GRP78, suggesting that the Pep42:GRP78 interaction may be responsible
for tumor binding selectivity. In order to validate this hypothesis, a polyclonal antibody was used
to block GRP78 on the surface of HepG2 cells, followed by treatment with FITC-labeled Pep42.
This resulted in a decrease in the fluorescence signaling from the FITC-Pep42 probe. A similar
decrease in fluorescence signaling from the FITC-Pep42 conjugate was observed following a
GRP78-silencing siRNA treatment, illustrating the importance of the GRP78 cell surface
receptor for Pep42 binding.
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Confocal laser scanning fluorescence microscopy was used to support the Pep42:GRP78
binding interaction on the surface of tumors and examine whether the peptide exhibited cell
permeability.1,3 In this study, a derivative of Pep42, Mut42, which replaced the valine at position
10 with a lysine to facilitate the incorporation of the FITC label was used to ascertain cell
translocation activity. It is imperative to note that this site specific substitution in Pep42 was not
found to alter its GRP78 binding activity. Thus, treatment of FITC-labeled Mut42 with
metastatic melanoma cells (Me6652/4) and the low metastatic control (Me6652/56) resulted in
greater uptake within the tumorigenic melanoma cells (Figure 5.2, i).1

Similarly, Mut42-

quantum dots (Mut42-QD) were prepared and applied for detecting cellular localization with
greater sensitivity relative to their fluorescent counterpart. In this case, the Mut42-QD probes
were found to translocate and localize within the cytosol of highly metastatic melanoma cells
without entering their nucleus. Further investigation revealed that the Mut42-QD co-localized in
the endoplasmic reticulum with the co-administration of Glibenclamide, a biomarker that stains
the ER (Figure 5.2, ii).
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Figure 5.2. Cell uptake (i.) and localization (ii.) of Mut42. i. Comparison of the cell uptake of
Mut42-FITC in (a) highly metastatic melanoma cells (Me6652/4) and (b) low metastatic
melanoma cells (Me6652/56). Mut42-FITC green signal apparent in (a) but not in (b). ii. Cellular
co-localization of Mut42-QD in the ER of highly metastatic melanoma cells (Me6652/4) with
Glibenclamide. Figure adapted from reference 1.

Confocal microscopy was also employed to elucidate the mechanism of Pep42 cell
translocation.3 A Pep42-QD was prepared and applied to discern the mechanism of
internalization in A549 osteocarcinoma cells. In this assay, Pep42 was found to partially colocalize with known markers of endocytosis such as transferrin and cholera toxin subunit B.
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Transferrin glycoproteins have been found to internalize within cells by an endocytosis pathway
which involves the formation of clathrin-coated vesicles at the cell surface.4 Whereas, the
cholera toxin subunit B internalizes within cells by caveolae-mediated endocytosis.5 In order to
delineate the endocytosis pathway of Pep42, several inhibitors of endocytosis were examined,
including chlorpromazine, a known inhibitor of clathrin mediated endocytosis.6 In its presence,
Pep42 and transferrin did not internalize within A549 osteocarcinoma cells; whereas
chlorpromazine had no effect on cholera toxin subunit B.3 These results suggests that Pep42, in
similar fashion to transferrin, internalizes within A549 osteocarcinoma cells by a clathrin-coated
endocytosis pathway.
In light of Pep42’s GRP78 targeting and internalization within cancer cell types but not in
healthy ones, Pep42 was tested as a targeting drug delivery agent for anti-cancer applications.1,3,7
Towards this goal, Pep42 has been effectively conjugated with cytotoxic anti-cancer drugs such
as Taxol and Doxorubicin, photosensitizers such as a functionalized hematoporphyrin for
applications in photodynamic therapy and the pro-apoptotic D-(KLAKLAK)2 sequence
triggering programmed cell death specifically in human cancer cells and in xenograft mouse
models.1,3,7 Thus, the highly specific Pep42:GRP78 ligand-receptor interaction may form the
basis for new and improved drug delivery methods in cancer treatment.

5.2.2 POLY(ARGININE) PEPTIDES AS siRNA CELL DELIVERY AGENTS
Poly(arginine) peptides encompass a special class of cell-penetrating peptides (CPPs) that
have the ability to participate in ionic binding interactions with negatively charged biomolecules
and cell-membrane translocation activity.8 Moreover, the number of arginine residues within the
CPPs have been found to influence membrane permeability, with poly(arginine) sequences
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containing in between 6-12 arginine residues eliciting optimal permeability and localization
within the cytosol or nucleus of the cell.8,9 Their translocation mechanism is still widely debated,
from which the nature of the arginine-rich sequence, its secondary structure and cell types have
each been found to influence its membrane permeability and cellular localization.8-10 Moreover,
poly(arginine) peptides have typically shown minimal cellular cytotoxicities9, facilitating their
applications in the delivery of biomolecules across the plasma membrane. Specifically,
poly(arginine) peptides have been employed in siRNA transfections due to their favorable ionic
binding interactions with the negatively charged phosphodiester backbone of the oligonucleotide
sequences. For example, human epidermal growth factor receptor 2 (HER-2) silencing siRNA
has been effectively transfected within Cos-7 cells and in subcutaneous tumor transplants in mice
with an arginine peptide (R15) leading to potent down-regulation of HER-2 mRNA and marked
decrease in tumor size over a 17 day treatment regimen (Figure 5.3).11 Although arginine-rich
peptides are highly efficient in mediating siRNA cellular uptake for RNAi activity in vitro and in
vivo, their translation from pre-clinical to clinical use has been hindered by poor specificity and
widespread toxicity, as these peptides and their cargo are dispersed in almost all tissues.12 In
order to address this limitation, cancer-targeting peptides have been associated with
poly(arginine) sequences to effect targeted cell delivery of siRNA in vitro and in vivo.13
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Figure 5.3. Tumor growth in xenograft mouse with (A) no treatment, (B) siRNA, (C)
R15:mismatch HER-2 siRNA and (D) R15:HER-2 siRNA following a 17 day treatment regimen.
Transfection of R15:HER-2 siRNA shrunk the tumor size by more than 7 times relative to the
un-treated control. Figure adapted from reference 11.

5.3 CHAPTER OBJECTIVES
This chapter sets the stage for the development and application of a cancer-targeting gene
therapy approach (Figure 5.4). Towards this ultimate goal, preliminary results are highlighted in
this chapter that demonstrates the effective formation of GRP78-targeting CTP:siRNA
complexes and their application in RNAi. This endeavor was partially accomplished in
collaboration with Stesha Joseph (Dr. Sabatino’s group) who synthesized and characterized the
CTPs used in this study and assisted in their complex formation/ characterization studies. TEM
and dynamic light scattering (DLS) measurements were obtained at Queens College with the
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assistance of Reeta Yadav, a graduate student in Dr. Samuni’s research group. Additionally,
Brittany Blackman, Christopher Parronchi, Megan Kelly (Dr. Blake’s group) and Mariana
Phillips (Dr. Sabatino’s group) have conducted the preliminary biological studies reported in this
chapter and continue to investigate the bio-activity of the CTP:siRNA constructs. More
specifically, complex formation between the CTP:siRNA ionic particles was validated by native
PAGE, thermal denaturation, CD spectroscopy, DLS and TEM experiments. These methods
served to elucidate the optimal stoichiometric ratios of the CTPs and siRNAs necessary for
complex formation, thermal stabilities, particle size distributions and the structures of the higherordered assemblies. Prior to RNAi application, the serum stability of the CTP:siRNA complexes
relative to their individual components was examined in 10% fetal bovine serum (FBS) to
determine their resistance towards degradation in biological media. With stable CTP:siRNA
complexes in hand, their potential in RNAi application is discussed en route towards the
development of an effective cancer-targeting approach.
Figure 5.4. Proposed cancer-targeting gene therapy strategy
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5.4 RESULTS AND DISCUSSION
5.4.1 PREPARATION AND CHARACTERIZATION OF CTP:siRNA COMPLEXES

With pure samples of linear, V-shape, Y-branch and

hyperbranch siRNAs (Table 2.1,

sequence no. 1-7) and CTPs containing the GRP78-targeting Pep42 with varying poly(arginine)
sequences14, the optimal stoichiometric ratio for CTP:siRNA complex formation was established
by native PAGE. Stoichiometric ratios of 1-50:1, CTP:siRNA were combined in an annealing
30% sucrose (Tris-Acetate-EDTA) TAE buffer pH 8.3, incubated for 30 min at 37 oC and loaded
on a native PAGE absent of urea. Samples were resolved on the native gel and detected by
staining with a Stains All™ dye (Aldrich) which forms a dark blue colored complex with the
oligonucleotides.15 From this gel shift assay, increasing mole ratios of a CTP (1.0-50 μmol, 1-50)
bearing a nona-arginine sequence (R9) relative to a single-stranded siRNA control (1.0 μmol,
Table 2.1, sequence 3) produced shifts in the electrophoretic mobilities of the forming
CTP:siRNA complexes (Figure 5.5). Specifically, at a stoichiometric ratio of 50:1 CTP:siRNA
formed a slower moving band indicative of a higher-ordered complex relative to the single strand
siRNA control.

Figure 5.5. Native PAGE gel shift assay. Linear single strand siRNA (1.0 μmol, Table 2.1,
sequence 3) and increasing (1-50:1) stoichiometric ratios of CTP (1.0 – 50 μmol, Pep42-R9).
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Similarly, this CTP sequence was found to effectively produce higher-ordered complexes at a
mole ratio of 50:1 with double-stranded, Y-shape and

hyperbranch siRNAs (Table 2.1,

sequence nos. 2, 5 and7) by native PAGE (Appendix C).

CD spectroscopy was then used to assess the changes in CTP and siRNA structures in their
free form and bound state (Figure 5.6). The cyclic Pep42-R9 sequence demonstrated a CD
spectrum that contained an ordered turn conformation with minimal random coil observed. Some
types of peptide turn geometries have been characterized by a minimum band at around 210 nm
and maximum molar ellipticities centered around 220 and 190 nm (Figure 5.6, i).16 Conversely,
disordered peptide structures or random coils have strong negative bands centered around 190
nm.17 The linear siRNA control (Table 2.1, sequence 1) demonstrated a typical CD profile for
the canonical double-stranded A-form RNA helix (Chapter 3), displaying a minimum peak at
around 240 nm and a broad maximum in between 255-290 nm (Figure 5.6, ii).18 In combination,
the CTP:siRNA complexes exhibited profound changes on their respective secondary structures
(Figure, 5.6, iii) and produced higher–ordered structures that were atypical of the putative CTP
turn conformation or siRNA A-type helix. Similar trends were observed for the remaining
CTP:siRNA complexes (Appendix D).

Figure 5.6. CD spectra of i. CTP: Pep42-R9 (0.1 mg/mL), ii. siRNA (0.26 μmol, Table 2.1,
sequence 1) and iii. CTP:siRNA complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl, 2.7
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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In order to determine the sizes, shapes and structures of the CTP:siRNA complexes, DLS
and transmission electron microscopy (TEM) experiments were conducted. DLS was initially
employed to investigate the size distributions of the particles formed between the CTP:siRNA
relative to their individual components (Table 5.1). DLS measurements of the effective
diameters (nm) observed from the nanoparticles indicated a uniform size distribution for the
CTP, Pep42-R9 (~ 40 nm) and aggregates for the linear siRNA (Table 2.1, sequence no. 2, 6001000 nm, and a monomer size of 20 nm). Comparatively, the CTP:siRNA complex (13 μM, 50:1
CTP:siRNA) displayed a bimodal size distribution according to the DLS measurements, with one
distribution occurring at around 210 nm and a much larger one at about 1400 nm. The latter
results in more than a 50-fold increase in CTP:siRNA particle size relative to the unbound
components, validating the formation of higher-ordered complexes. Similar trends were observed
from the DLS measurements obtained for the CTP:siRNA complexes formed in between the
Pep42-R9 sequence and the Y-shape (Table 2.1, sequence no. 5),

hyperbranch (Table 2.1,

sequence no. 7) siRNAs (Appendix E).

Table 5.1 DLS measurements of the effective diameters (nm) observed.a

Samples

Effective Diameters (nm)

CTP, Pep42-R9

40 ± 4

Linear siRNA, 2 (monomers)

~ 20

CTP:siRNA

210 ± 14
1400 ± 80

a

Samples (0.05-0.15 μM) were prepared in pre-filtered (0.2 μm filter) pH 7.0 phosphate buffer

(140 mM KCl, 1 mM MgCl2, 5 mM NaHPO4) and sonicated for 30 minutes before taking
measurements. The reported diameter is the average of 5 runs for each sample reported with
standard deviations about the mean.
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The TEM images provided an illustration of the shapes and structures formed from the
CTP:siRNA complexes (Figure 5.7). In the case of the complex formed between a CTP, Pep42R9 and a linear siRNA sequence (Table 2.1, sequence no. 2) the particles appeared as spherical
shaped aggregates with approximate diameters of 1000 nm, that were in agreement with those
observed from the DLS measurements. Moreover, similar results were also obtained for the
remaining CTP:siRNA complexes (Appendix F), highlighting the efficiency of the Pep42-R9
sequence in condensing siRNAs of varying lengths, sequences and morphologies. These results
were also in agreement with the TEM images reported for a myristoylated cell-penetrating
peptide with a transferrin receptor-targeting sequence bound to siRNA for RNAi application.19
Thus, the ability for the CTP sequence to effectively condense siRNA into stable nanoparticle
formulations is an important requirement for their biological applications.

Figure 5.7. TEM image of the complex formed between Pep42-R9 and linear siRNA (Table 2.1,
sequence no. 2). Samples (0.13 μM) were mixed with 1% uranyl acetate in ethanol (1:1 v/v),
sonicated for 10 minutes, and added to a carbon film coated copper grid, 300 mesh (Electron
Microscopy Sciences, PA) and dried overnight prior to viewing under the transmission electron
microscope (JEOL, model JEM-1200 EX). Images were taken with a SIA–L3C CCD camera
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(Scientific Instruments and Applications, Inc., GA) using the software Maxim DL5 (Diffraction
Limited, Ottawa, Canada).

Thermal denaturation experiments were next conducted to determine the thermal stability
of the CTP:siRNA complex. In the absence of peptide, the double-stranded siRNA (Table 2.1,
sequence no. 2) exhibited a helix-to-coil transition18 with increasing temperatures (5-90 oC) that
produced a noticeable change in hyperchromicity (%H: 5-30%) and thermal denaturation
temperature (Tm: 72 oC). This data is consistent with that reported for the linear, V-shape, Ybranch and

hyperbranch siRNAs described in this study (Chapter 3). Titration of CTP (0.26 –

13 μmol) to siRNA (0.26 μmol) produced striking changes in the thermal denaturation curves
(Figure 5.8). These changes were associated with a sharp decrease in hyperchromicities (30% to
≤10%) which abolished the single phase transition observed in the control (free-form) siRNA.
Presumably, at optimal CTP:siRNA (15 μM, 50:1 mol/mol) concentrations the siRNA no longer
exhibits the characteristic biophysical traits of a double-stranded RNA hybrid. Similar trends
were observed in the thermal denaturation curves of the remaining CTP:siRNA complexes
(Appendix G).
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Figure 5.8. Thermal denaturation studies of the CTP:siRNA complex. Samples were prepared by
mixing CTP:siRNA (15 μM, 1-50:1 mol/mol) in phosphate buffer (140 mM KCl, 1 mM MgCl2,
5 mM NaHPO4) and placing on a heat block incubator set at 37 oC for 1 hour. Samples were
cooled to room temperature and placed in the fridge overnight for use the next day.

5.4.2 BIOLOGICAL STUDIES OF THE CTP:siRNA COMPLEXES
The ability for the CTP:siRNA complexes to retain metabolic stability is an important
requirement for their fruitful RNAi applications. This is because the native siRNA sequences are
typically prone to nuclease digestion in biological media, limiting their therapeutic potential. 20
Samples were subjected to a 10% fetal bovine serum (FBS) in Dulbecco’s Modified Eagle
Medium (DMEM) treatment in order to test the metabolic stability of the CTP:siRNA complex
relative to the free-form siRNA. Aliquots were taken at measured time point intervals and run on
a denaturing (urea) PAGE to resolve the samples. Stains-All™ (Aldrich) detection produced the
desired siRNA bands with and without the CTP (Figure 5.9). Excitingly, the CTP:siRNA
complexes remained intact up to 8 hours, (Figure 5.9, B) while in the naked siRNA produced
short degradation products that were visible as lower migrating bands on the gel even after 5
minute FBS treatment (Figure 5.9 A). The ability of peptides to confer nuclease resistance to
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siRNA is not unexpected, peptide:siRNA complexes remained stable (> 8 hours) while the freeform siRNA was completely degraded within 4 hours in 50% FBS.19

Figure 5.9. 18% native (no urea) PAGE of (A) siRNA (20 μM) and (B) CTP:siRNA (20 μM) in
10% FBS in DMEM. Samples were incubated (0.15 mL, 10% FBS/DMEM) at 37 oC and at
measured time points, aliquots (10 μL) were treated with gel loading buffer (10 μL of 80 %
formamide in TBE), heated at 95 oC and resolved on denaturing PAGE. The gels were stained
with Stains-All™ (Aldrich) to view the siRNA decomposition patterns.

With stable constructs in hand, the RNAi activity of the CTP:siRNA complex was next
evaluated in HepG2 cells (Figure 5.10). A CTP:siRNA complex (50:1 mole ratio, 20 M) was
prepared in a suitable binding buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA)
for transfection within the HepG2 monolayers. The cells were incubated and cultured (48 h, 37
o

C, 5% CO2) prior to analysis. Following incubation, cell lysates were prepared (RIPA lysis

buffer, Invitrogen) and resolved by SDS PAGE, transferred to a PVDF membrane and
immunoblotted with an anti-GRP78 primary antibody and a secondary antibody coupled to
horseradish peroxidase (HRP). GRP78 expression levels were detected by autoradiography
which produced reduced GRP78 (~50%) at quantities that were comparable to the benchmark
Lipofectamine:siRNA transfections reported in Chapter 4. This experiment thus validates the
utility of the CTP as an siRNA transfection agent for RNAi activity in HepG2 cells (Figure 5.10,
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A, B). Finally, a Trypan blue cell staining assay was used to track the number of dead HepG2
cells (~15%) following GRP78 silencing (Figure 5.10, C).

Figure 5.10. RNAi activity of CTP:siRNA complex. (A) Western blot and (B) data analysis by
autoradiography of GRP78 expression (n=1) following CTP:siRNA transfection (0, 40 and 80
pmol siRNA, 50:1 mole ratio CTP:siRNA, in Tris buffer pH 8). (C) Cell viability data (0, 40 and
80 pmol siRNA, 50:1 mole ratio CTP:siRNA, 20 µM in 50 µL of OPTIMEM) determined by
Trypan blue exclusion (mean  S.E.M.; n=3, *P< 0.05).

5.5 CONCLUSIONS
An entry point into a cancer-targeting gene therapy approach has been realized. In this
chapter, a representative CTP:siRNA complex has been formulated and characterized by
electrophoresis, spectroscopy and microscopy. Moreover, the CTP:siRNA complex was entirely
stable (up to 8 hours) to a 10% FBS in DMEM treatment, highlighting the shielding effects of the
CTP in protecting the siRNA from nuclease degradation in biological media. This feature is an
imperative requirement for increasing the therapeutic index of the siRNA in the RNAi
application.20 Towards this effect, the GRP78-targeting CTP:siRNA complex effectively downregulated GRP78 expression (~50%) in HepG2 hepatoblastoma cells while triggering noticeable
apoptosis (~15%). Thus, the CTP:siRNA complexes formulate an effective transfection strategy.
Future work is geared towards validating the remaining siRNAs (Chapter 2, Table 2.1) for RNAi
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application, while exploring the influence of the poly(arginine) sequences on Pep42 targeted
delivery of the siRNAs in GRP78 overexpressing tumors. The latter forms the basis of our
cancer-targeting gene therapy approach, which has been partially realized by the notable
contributions highlighted in this thesis.
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5.7 EXPERIMENTAL SECTION
5.7.1 CTP:siRNA COMPLEX FORMATION
Pep42-R9 was added in increasing stoichiometric quantities (0.50 – 25 μmol) relative to the
siRNA (0.50 μmol) in annealing buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA).
The samples were incubated at 37 oC for 1 hour and left to cool down to room temperature and
stored in the fridge (4 oC) overnight prior to use the next day.

5.7.2 CTP:siRNA STABILITY IN 10% FBS/DMEM
CTP:siRNA complexes and native siRNAs were incubated in 10% FBS/DMEM (150 μL) at 37
o

C. Aliquots (10 μL) were removed at set time intervals (0-24 h), treated with gel loading buffer

(10 μL of 80 % formamide in TBE loading buffer) and heated at 95 oC to quench the reactions.
Samples were loaded and resolved on an 18% denaturing PAGE (7M urea) and visualized with
Stains-All™ (Aldrich) to determine the siRNA integrity.

5.7.3 GEL SHIFT ASSAY
CTP:siRNA complexes (15 M, 1-50:1 mol/mol) were analyzed by native (no urea) PAGE.
Samples were prepared by adding stoichiometric ratios (1-50:1) of CTP:siRNA in 30% sucrose
in 1X TAE loading buffer (10 μL). Samples were incubated at 37 oC for 1 hour, cooled to room
temperature and stored at 4 °C overnight. A 18% native PAGE was prepared using 5 mL of 10X
TBE buffer, 22.5 mL (acrylamide and N,N-methylene bisacrylamide) and 22.5 mL of autocalved
water. The gel was run at 500 V for 2.5 h and stained with Stains-All™ (Aldrich) to visualize the
CTP:siRNA bands.
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5.7.4 DYNAMIC LIGHT SCATTERING (DLS)
DLS measurements were performed on a 90 plus particle size analyzer (Brookhaven Instruments
Corporation, NY) employing a 90° scattering angle and a 35 mW incident laser (658 nm).
Samples were diluted in a pH 7 buffer consisting of 140 mM KCl, 1 mM MgCl2, 5 mM NaHPO4
and sonicated for 30 minutes before taking measurements. The reported diameter is the average
of 5 runs for each sample with the corresponding standard deviation.

5.7.5 TRANSMISSION ELECTRON MICROSCOPY (TEM)
The diluted samples from the DLS measurements were mixed in a 1:1 (v/v) ratio with 1% uranyl
acetate in ethanol and sonicated for 10 minutes. An aliquot (5 L) was transferred to a carbon
film coated copper grid, 300 mesh (Electron Microscopy Sciences, PA) and the excess solution
was removed immediately using an absorbent paper. The grids were dried overnight and viewed
under the transmission electron microscope (JEOL, model JEM-1200 EX). Images were taken
with a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc., GA) using the
software Maxim DL5 (Diffraction Limited, Ottawa, Canada).

5.7.6 HepG2 CELL CULTURE
The human hepatoblastoma, HepG2 cells (American Type Culture Collection, VA) were
cultured in T25 cm2 and T75 cm2 flasks (Grenior Bio-one Cell star, FL) in Dulbecco’s Modified
Eagle Medium (DMEM) with GlutaMAX and heat-inactivated 10% Fetal Bovine Serum (Gibco,
CA), containing 1% penicillin/streptomycin (Gibco, CA), in an incubator set at 37 oC with a
humidified atmosphere of 5% CO2. Cells were routinely passaged at 75% confluence using
Dulbecco’s PBS (Gibco, CA) and 0.05% Trypsin-EDTA (1X), Phenol Red (Gibco, CA) and then
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split into a 1:10 dish ratio. Cells used in the transfection experiments were cultured in 6- 96-well
culture plates and allowed to recover for 24 hours before treatment.

5.7.7 CTP:siRNA TRANSFECTION IN HepG2 CELLS
HepG2 cells were transfected with the appropriate siRNA, 1, (40-80 pmol) and CTP (4.0
nmol) in binding buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA). The cell
monolayers were plated and incubated at 37 C with 5% CO2. After 24 h, the serum free basal
medium was removed and replaced with growth medium. Transfected cells were harvested (48
h) after transfection for analysis.

5.7.8 SDS-PAGE AND WESTERN BLOTTING
Cell lysates were prepared with RIPA lysis buffer, heated to 70 ˚C for 10 min., resolved
on NuPAGE 10% Bis-Tris gels and electroblotted onto polyvinyldifluoride (PVDF) membranes.
Membranes were treated for 90 min in a blocking buffer containing 5% (w/v) of non-fat
dehydrated milk to minimize non-specific binding. Total HepG2 cells’ GRP78 expression was
immunodetected with a 1:200 dilution of anti-GRP78 N-20 antibodies.

The membrane

associated immunoreactivity was then detected using a 1:5000 dilution of a horseradish
peroxidase-conjugated

anti-goat

secondary

antibody

and

detected

using

ECL

Plus

chemiluminescence. The resulting autoradiograph was scanned, quantified with NIH ImageJ and
expressed as integrated pixel density.

5.7.9 CELL VIABILITY
Cell viability was determined in 24-well plates with HepG2 cells cultured in serum-free
basal medium for 24 h and then incubated in the presence or absence of varying concentrations
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of CTP:siRNA (20 M) for 48 h at 37

o

C. The samples were removed with Enzyme Free

Dissociation Buffer for 3 minutes at 37 C. Samples were pelleted and re-suspended in
Dulbucco’s PBS (1 mL) and Trypan blue 0.4% stain (100 µL) was added. Samples were
quantified using a Countess automated cell counter. The resulting data was analyzed with
GraphPad Prism 4.0 and statistical significance was determined by ANOVA (p< 0.05).
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CHAPTER 6. CONCLUSION AND CONTRIBUTIONS TO KNOWLEDGE
6.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS
THESIS

6.1.1 SYNTHESIS AND CHARACTERIZATION OF BRANCH AND HYPERBRANCH
siRNAs
The solid phase synthesis and characterization of a new brand of siRNAs (Figure 2.9)
has been disclosed in Chapter 2 of this thesis. The siRNA sequences were derived from multiple
sites of GRP78 mRNA, an oncogene known to trigger cancer proliferation and resistance in a
wide range of tumors. Therefore, potent silencing of GRP78 mRNA has been shown to
compromise cancer cell activity leading to the development of potent anti-cancer approaches.
Towards this unified goal, novel V-shape, 2.8, Y-branch, 2.9, and

hyperbranch, 2.10-2.11,

siRNAs were synthesized by an efficient semi-automated solid phase synthesis method,
producing a library (17) of GRP78-silencing siRNAs for exploring structure-activity
relationships in cancer. Notably, the synthesis procedure featured the use of either 5’-OLv 2’-or
3’-OMMT ribouridine phosphoramidite branchpoint nucleotides (Scheme 2.2, 2.16 and 2.24), to
procure the branch and hyperbranch siRNAs in good yields (17-83%) and purities (≥90%)
following ion pairing reverse-phase HPLC analysis and purification. The sequence identities of
the siRNAs were confirmed by molecular weight analyses using ESI-MS (Novatia Inc, Newton
PA), whereas denaturing and native PAGE were used to respectively confirm siRNA purity and
hybridization for bio-physical and structural studies.
The biophysical traits and structural characteristics of the newly formed branch and
hyperbranch siRNAs were also evaluated for the first time in Chapter 3 of this thesis. Namely,
CD spectroscopy was used to investigate siRNA secondary structure to ascertain the A-type
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helix in the newly formed siRNAs. This helical trajectory is a requirement for RISC recognition
of the siRNA substrates for mRNA silencing activity. Moreover, thermal denaturation
experiments using UV-Vis spectrophotometry were used to evaluate hybrid thermal stability.
Interestingly, branch and hyperbranch siRNAs displayed stable hybrid structures (Tm: 68 - >90
o

C) relative to the linear controls (Tm: 67 - 76 oC), and in some cases were found to contain

multiple hybrid-to-single-strand transitions due to the multiple siRNA motifs embedded within
these types of higher-ordered structures. From these spectroscopic studies, branch and
hyperbranch siRNAs were found to display the pre-requisite hybrid structures for stimulating
RNAi activity in cancer.

6.1.2 GRP78 SILENCING AND CELL DEATH ACTIVITY OF BRANCH AND
HYPERBRANCH siRNAs IN HepG2 CANCER CELLS
In this study, the RNAi activity of the GRP78-silencing branch and hyperbranch siRNAs
(Table 2.1, sequence no. 4-7) has been validated for the first time in HepG2 hepatoblastomas.
HepG2 cells have been shown to overexpress and cell surface localize GRP78, thereby forming a
valid tumor cell line model for validating the proposed GRP78-silencing strategy and a clinically
relevant form of pediatric liver cancer for exploring new and improved forms of therapy. In
chapter 4, the novel V-shape, Y-branch, and

hyperbranch siRNA motifs (Table 2.1, sequence

no. 4-7) were found to trigger potent GRP78 silencing (50% – 60%) while eliciting noticeable
apoptosis (~5 - 15%) in HepG2 cells. Significantly, hyperbranch siRNA, 7, targeting GRP78
mRNA expression at distinct sites was found to trigger more potent GRP78 silencing (60% vs.
40%) and HepG2 cell death (15% vs. 5%) activity relative to the linear siRNAs, 1 and 2,
highlighting its synergistic effects. This finding is important for the development of new siRNA
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constructs that may target multiple genes in a combination approach for improving the RNAi
effect. Moreover, confocal laser scanning microscopy also supported the western blot data, by
illustrating significant cell surface GRP78 silencing (~70%) with hyperbranch siRNA, 7.
Interestingly, FITC-labeling of cell surface GRP78 on HepG2 cells also suggests the possibility
of developing tumor-targeting strategies (Chapter 5).
In Chapter 5, the first steps towards the development of a cancer-targeting gene therapy
approach are highlighted, by the combination of GRP78-targeting siRNAs and peptides (i.e.
cancer-targeting peptides, CTPs). In this approach, GRP78-silencing siRNAs are combined with
poly(arginine) derived CTPs for the selective delivery of siRNAs into GRP78 HepG2 cells for
RNAi and cell death activity. The CTP:siRNA complexes were effectively characterized by
native PAGE, CD spectroscopy, thermal denaturation, DLS and TEM experiments. Moreover,
the transfection of GRP78 silencing siRNA (Table 2.1, sequence no. 1) with a CTP derived
from the Pep42-R9 sequence demonstrated significant GRP78 silencing (50-60%) and modest
cell death (5-15%) in HepG2 cells which were in agreement with the Lipofectamine:siRNA
transfection studies (Chapter 4). These results highlights the utility of the Pep42-R9 sequence as
a useful transfection reagent that may be applicable in a wide range of tumors that display the
cell surface GRP78 antigen. This discovery is also important for the development of an effective
cancer-targeting gene therapy approach, which aims to kill cancer cells selectively, while leaving
the healthy ones unmarked.
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Figure A10. IP RP LC/MS Analysis of (Table 2.1, sequence 1b)
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Figure A11. IP RP LC/MS Analysis of (Table 2.1, sequence 2a)
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Figure A12. IP RP LC/MS Analysis of (Table 2.1, sequence 2b)
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Figure A13. IP RP LC/MS Analysis of (Table 2.1, sequence 4)
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Figure A14. IP RP LC/MS Analysis of (Table 2.1, sequence 5)
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Figure A15. IP RP LC/MS Analysis of (Table 2.1, sequence 6)
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Figure A16. IP RP LC/MS Analysis of (Table 2.1, sequence 8)
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Figure A17. IP RP LC/MS Analysis of (Table 2.1, sequence 9)
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Figure A18. IP RP LC/MS Analysis of (Table 2.1, sequence 10)
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Figure A19. IP RP LC/MS Analysis of (Table 2.1, sequence 11)
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Figure A20. IP RP LC/MS Analysis of (Table 2.1, sequence 12a)
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Figure A21. IP RP LC/MS Analysis of (Table 2.1, sequence 12b)
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Figure A22. IP RP LC/MS Analysis of (Table 2.1, sequence 14)
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Figure A23. IP RP LC/MS Analysis of (Table 2.1, sequence 15)
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Figure A24. IP RP LC/MS Analysis of (Table 2.1, sequence 16)

A22

Figure A25. IP RP LC/MS Analysis of (Table 2.1, sequence 17)
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C. CTP:siRNA PAGE
Figure A26. Native gel analysis of Pep42-R9:siRNA
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D. CTP:siRNA analysis by CD Spectroscopy
Figure A27. CTP:siRNA analyses by CD Spectroscopy
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E. DLS studies of the CTP:siRNA complexes
Table A1.

Summary table of CTP:siRNA studies by
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DLS and TEM
F. TEM images of the CTP:siRNA complexes
Figure A28.

TEM images of Pep42:siRNA
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G. Thermal melts analysis of CTP: siRNA complex
Figure A29.

Thermal melts analyses of CTP:siRNA
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APPENDIX A. Supplemental NMR Spectra
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Figure A2.
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C NMR spectrum of 5’-O-levulinyl ribouridine, 2.21
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Figure A3.

1

H NMR spectrum of 5’-O-levulinyl 2’-O-monomethoxytrityl ribouridine, 2.22
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Figure A4.

13

C NMR spectrum of 5’-O-Levulinyl 2’-O-monomethoxytrityl ribouridine, 2.22
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Figure A5.

1

H NMR spectra of 5’-O-levulinyl 3’-O-monomethoxytrityl ribouridine, 2.23
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Figure A6.
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C NMR spectra of 5’-O-levulinyl 3’-O-monomethoxytrityl ribouridine, 2.23
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Figure A7.

31

P NMR spectra of 5’-O-levulinyl 2’-O-monomethoxytrityl 3’-O-

phosphoramidous ribouridine, 2.16
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31

P NMR spectra of 5’-O-levulinyl 2’-O-monomethoxytrityl 2’-O-

phosphoramidous ribouridine, 2.24
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APPENDIX B. Supplemental IP RP HPLC Chromatograms and MS spectra
Figure A9. IP RP LC/MS Analysis of (Table 2.1, sequence 1a)

Sequence 1a.
5′-A GUG UUG GAA GAU UCU GAU-3′
MS.

Calc. 6103.7 g/mol

Found 6103.7 g/mol

A7

Figure A10. IP RP LC/MS Analysis of (Table 2.1, sequence 1b)

Sequence 1b.
5′- A UCA GAA UCU UCC AAC ACU -3′
MS.

Calc. 5947.4 g/mol

Found 5949.4 g/mol
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Figure A11. IP RP LC/MS Analysis of (Table 2.1, sequence 2a)

Sequence 2a.
5′-G GAG CGC AUU GAU ACU AGA-3′
MS.

Calc. 6124.5 g/mol

Found 6124.7 g/mol
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Figure A12. IP RP LC/MS Analysis of (Table 2.1, sequence 2b)

Sequence 2b.
5′-UCU AGU AUC AAU GCG CUC C-3′
MS.

Calc. 5955.3 g/mol

Found 5958.6 g/mol
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Figure A13. IP RP LC/MS Analysis of (Table 2.1, sequence 4).

Sequence 4.
2’3’ UCA CAA CCU UCU AAG ACU A-5’
5’-rU
3’5’ AGU GUU GGA AGA UUG UGA U-3’
MS.

Calc. 12412.5 g/mol Found 12420.5 g/mol
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Figure A14. IP RP LC/MS Analysis of (Table 2.1, sequence 5).

Sequence 5.
2’3’ UCA CAA CCU UCU AAG ACU A-5’
5’– UCA CAA CC – 3’5’-rU
3’5’ AGU GUU GGA AGA UUG UGA U-3’
MS.

Calc. 14936.0 g/mol Found 14934.9 g/mol
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Figure A15. IP RP LC/MS Analysis of (Table 2.1, sequence 6).

Sequence 6.
3’-U AGU CUU AGA GGA UUG UGA-5’2’
2’3’ UCA CAA CCU UCU AAG ACU A-5’
rU3’5’–UCA CAA CC – 3’5’-rU
5’-A UCA GAA UCU CCU AAC ACU-3’5’
3’5’ AGU GUU GGA AGA UUG UGA U-3’

MS.

Calc. 27419.5 g/mol

Found 27450.0 g/mol
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Figure A16. IP RP LC/MS Analysis of (Table 2.1, sequence 8).

Sequence 8.
2’5’ AGU GUU GGA AGA UUG UGA U-3’
5’-rU
3’3’ UCA CAA CCU UCU AAG ACU A-5’
MS.

Calc. 12420.5 g/mol Found 12428.0 g/mol
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Figure A17. IP RP LC/MS Analysis of (Table 2.1, sequence 9).

Sequence 9.
2’5’ AGU GUU GGA AGA UUG UGA U-3’
5’– UCA CAA CC – 3’5’-rU
3’3’ UCA CAA CCU UCU AAG ACU A-5’
MS.

Calc. 14934.9 g/mol

Found 14941.6 g/mol
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Figure A18. IP RP LC/MS Analysis of (Table 2.1, sequence 10)

Sequence 10.
5’-A UCA GAA UCU CCU AAC ACU-3’3’
2’5’ AGU GUU GGA AGA UUG UGA U-3’
rU2’5’– UCA CAA CC – 3’5’-rU
3’-U AGU CUU AGA GGA UUG UGA-5‘5’
3’3’ UCA CAA CCU UCU AAG ACU A-5’

MS.

Calc. 27419.5 g/mol

Found 27668.8 g/mol
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Figure A19. IP RP LC/MS Analysis of (Table 2.1, sequence 11)

Sequence 11.
5’-U CUA GUA UCA AUG CGC UCC-3’3’
2’5’ AGU GUU GGA AGA UUG UGA U-3’
rU2’5’– UCA CAA CC – 3’5’-rU
3’-A GAU CAU AGU UAC GCG AGG-5‘5’
3’3’ UCA CAA CCU UCU AAG ACU A-5’

MS.

Calc. 27449.5 g/mol Found 27485.2 g/mol
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Figure A20. IP RP LC/MS Analysis of (Table 2.1, sequence 12a)

Sequence 12a.
5′- A UCA GAA UCU UCC AAC ACU -3′
MS.

Calc. 6075.0 g/mol

Found 6076.0 g/mol

Note: Underlined residues refers to 2’-OMe RNA
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Figure A21. IP RP LC/MS Analysis of (Table 2.1, sequence 12b)

Sequence 12b.
5′-A GUG UUG GAA GAU UCU GAU-3′
MS.

Calc. 6214.9 g/mol

Found 6215.9 g/mol

Note: Underlined residues refers to 2’-OMe RNA
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Figure A22. IP RP LC/MS Analysis of (Table 2.1, sequence 14)

Sequence 14.
2’3’ UCA CAA CCU UCU AAG ACU A-5’
5’-rU
3’5′-A GUG UUG GAA GAU UCU GAU-3′
MS.

Calc. 12658.8 g/mol

Found 12659.9 g/mol

Note: Underlined residues refers to 2’-OMe RNA
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Figure A23. IP RP LC/MS Analysis of (Table 2.1, sequence 15)

Sequence 15.
2’3’ UCA CAA CCU UCU AAG ACU A-5’
5’– UCA CAA CC – 3’5’-rU
3’5′-A GUG UUG GAA GAU UCU GAU-3′
MS.

Calc. 15229.5 g/mol

Found 15230.5 g/mol

Note: Underlined residues refers to 2’-OMe RNA
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Figure A24. IP RP LC/MS Analysis of (Table 2.1, sequence 16)

Sequence 16.
3’-U AGU CUU AGA GGA UUG UGA-5’2’
2’3’-UCA CAA CCU UCU AAG ACU -5’
rU3’5’– UCA CAA CC – 3’5’-rU
5’- A UCA GAA UCU UCC AAC ACU-3’5’
3’5′-A GUG UUG GAA GAU UCU GAU-3′

MS.

Calc. 27840.2 g/mol

Found 28141.9 g/mol

Note: Underlined residues refers to 2’-OMe RNA
Figure A25. IP RP LC/MS Analysis of (Table 2.1, sequence 17)
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Sequence 17.
3’-A GAU CAU AGU UAC GCG AGG -5’2’
2’3’-UCA CAA CCU UCU AAG ACU -5’
rU3’5’– UCA CAA CC – 3’5’-rU
5′-U CUA GUA UCA AUG CGC UCC-3’5’
3’5′-A GUG UUG GAA GAU UCU GAU-3′

MS.

Calc. 27870.2 g/mol

Found 27766.3 g/mol

Note: Underlined residues refers to 2’-OMe RNA
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APPENDIX C. CTP:siRNA PAGE

Figure A26. Native gel analysis of Pep42-R9 and (A)Table 2.1 sequence 2; (B) Table 2.1
sequence 5 and (C) Table 2.1 sequence 7.
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APPENDIX D. CTP:siRNA analysis by CD Spectroscopy
Figure A27. CTP:siRNA analysis by CD Spectroscopy. (A) Table 2.1 Sequence 2, (B) Table
2.1 Sequence 5, (C) Table 2.1 Sequence 7.
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APPENDIX E: DLS studies of CTP:siRNA
Table A1. Summary table showing CTP:siRNA studies by DLS and TEM
Effective Diameter from DLS
(nm)

Comments

~ 20
600-1000

monomers
mostly aggregates

Pep42-r9: seq. 2 (50:1)

210 ± 14
1400 ± 80

Bimodal complex

Sequence 5 (Y siRNA)

20 ± 5
700 -2000

monomers
aggregates

Pep42-r9: seq. 5 (50:1)

900 ± 50
170 ± 9

Bimodal complex

~ 20
20-2000

monomers
mostly aggregates

Sample
Sequence 2 (Duplex
siRNA)

Sequence 7
(Hyperbranch siRNA)

Pep42-r9: seq. 7 (50:1)

340 ± 2

CTP:siRNA (Pep42-R9:siRNA, Sequence no. 2)
The DLS and TEM both show complex formation with approximately similar sizes around 1000
nm. However sequence 2 alone is highly aggregated with unstable DLS readings and high
aggregation seen on TEM grids. This supports the conclusion that complexes are formed because
the complex duplex is uniform and looks different on TEM grids.

CTP:siRNA (Pep42-R9:siRNA, Sequence no. 5)
The TEM and DLS results show the population of 170 nm as well as 900 nm population on DLS.
Complex formation is supported by the observation of uniform complexes seen on grids which
are not seen in the controls. Sequence 5 alone has a DLS population 5 nm, while on TEM
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uniform particles of approx. 20-25 nm were observed. In both cases the sequence 5 sizes alone
are smaller than the sizes seen in complexed samples.

CTP:siRNA (Pep42-R9:siRNA, Sequence no. 7)
About 340 nm complex size is observed in both DLS and TEM (300 – 500nm) . Also seen are
smaller sized particles (approx. 100-300 nm) which could be smaller complexes. Sequence 7
alone is multimodal with different populations and high aggregation suggested by DLS and
TEM. The monomeric form is approximately 25 nm, some particles of size 100 nm are seen and
a few aggregates ranging from 700 -2000 nm are seen.

In all three cases there seems to be complex formation, as deduced from TEM images. DLS data
does not always correlate with the TEM sizes especially as seen in the siRNA sequences alone,
mostly due instability or multimodal populations showing aggregation. Sample preparation for
TEM could also be a contributing factor to slight changes observed when comparing DLS and
TEM.
APPENDIX F. TEM images of CTP:siRNA
Figure A28. TEM images of Pep42-R9 and (A) Table 2.1 sequence 2; (B) Table 2.1 sequence
5 and (C) Table 2.1 sequence 7. Data explanation provided in Appendix E.
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APPENDIX G. Thermal melts of CTP: siRNA
Figure A29. Thermal melts of CTP:siRNA between Pep42-R9 and (A) Table 2.1 sequence 2,
(B) Table 2.1 sequence 5 and (C) Table 2.1 sequence 7.
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